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ABSTRACT 
Objective: To determine whether serum phthalate concentrations differ in men and women with 
infertility compared to those without infertility in Saskatchewan  
Hypothesis: Serum phthalate concentrations will be greater in men and women with infertility 
compared to fertile men and women 
Setting: Patients undergoing assisted reproduction for the treatment of infertility; healthy 
volunteers recruited from the community 
Recruitment and sample collection: Infertile couples were recruited prior to in vitro 
fertilization (IVF) therapy for treatment of unexplained infertility (n=15), polycystic ovarian 
syndrome (PCOS, n=13), and male factor infertility (n=12); fertile men (n=15) and women 
(n=15) were recruited using poster advertisements.  Blood samples were collected by 
venipuncture for phthalate analysis. 
Main outcome measures: Serum phthalates concentrations (ng/mL)  
Design: Prospective cohort pilot study 
Methods: In infertile couples, blood samples were collected on the following 3 days of the IVF 
cycle: early during ovarian stimulation, day of oocyte retrieval and day of embryo transfer.  In 
healthy volunteers, 3 blood samples were collected over a 2 week period. Liquid 
chromatography and tandem mass spectrometry (LC-MS/MS) was conducted to quantify 
concentrations of four phthalates: di-n-butyl phthalate (DBP), diethyl phthalate (DEP), di-(2-
ethylhexyl) phthalate (DEHP) and diisodecyl phthalate (DIDP).  Phthalate concentrations were 
compared among the four study groups using non-parametric Kruskal-Wallis and Mann-Whitney 
U post hoc tests. 
Results: Serum DEHP and DEP concentrations did not differ among control, unexplained, 
PCOS, and male factor infertility groups in both men and women (p>0.05).  DBP in women did 
not differ among study groups (p=0.205).  In contrast, DBP was lesser in men with unexplained, 
PCOS, and male factor infertility compared to controls (p < 0.05).  Similarly, DIDP was lesser in 
women of couples with unexplained, PCOS and male factor infertility groups compared to fertile 
women (p < 0.05).  Less DIDP was detected in men with unexplained and male factor infertility 
compared to the control group (p < 0.05) 
Conclusion: Serum phthalate concentrations in serum were lesser or not different in infertility 
patients undergoing IVF compared to fertile volunteers.  These findings do not support the 
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notion that serum phthalate concentrations are associated with human infertility.  Further 
research is needed to determine whether phthalate concentration in blood cells and adipose tissue 
differ in infertile versus fertile men and women. 
Key words: Phthalates, PCOS, Unexplained infertility, Male factor infertility  
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CHAPTER 1: GENERAL INTRODUCTION 
The human endocrine system is highly complex.  The main functions of the endocrine 
system are to synthesize and release hormones, which regulate the growth, development, and 
metabolism of organs and body systems.  In addition to endogenous endocrine hormones, many 
chemicals in the environment can affect endocrine function.  Endocrine disrupting chemicals 
(EDCs) are defined as exogenous agents that interfere with the synthesis, secretion, transport, 
binding, action and/or elimination of natural hormones responsible for the maintenance of 
homeostasis, reproduction, development and behavior (1).  Endocrine disrupting chemicals can 
mimic or interfere with the action of endogenous endocrine hormones, including reproductive, 
thyroid, adrenal and pituitary hormones.   
The relationship between EDCs and health has been investigated in animals and to a 
lesser extent in humans over the past 50 years.  A growing body of evidence suggests that EDCs 
may be associated with a wide range of diseases and disabilities including obesity, diabetes, 
cancer, heart disease, thyroid disease, reproductive dysfunction, as well as neurodevelopmental 
and neurodegenerative disorders (2).  Reproductive dysfunction and abnormal fetal development 
have been shown to be related to EDC exposure in many animals (3-5).  Endocrine disrupting 
chemicals may exert their effects by a number of mechanisms including: 1) acting as estrogen 
agonist or aryl hydrocarbon receptor agonist, 2) acting as estrogen or androgen antagonist, 3) 
altering steroidogenic enzyme gene expression, 4) disrupting gonadotropin hormone production, 
5) indirectly interfering with steroidogenesis by alteration of cell membrane ion exchange, 6) 
inducing epigenetic changes, and/or 7) inducing oxidative stress (6-11).  In addition, direct 
effects on gametes (i.e., oocytes, sperm) have been observed (12). 
Hundreds of natural and man-made EDCs are present in the environment.  More than 
500 chemicals are known or suspected to have endocrine disrupting potential (13, 14).  
Bisphenol A (BPA) and phthalates are 2 groups of man-made EDCs of particular concern 
because of their high production, widespread use and omnipresence (5).  Women, men and 
children are continuously exposed to BPA and phthalates through contaminants in the air, 
water, soil, dust, construction materials, children’s products, personal care products (e.g., 
perfumes, lotions and cosmetics), paints, medical devices, pharmaceuticals and many more.  
Phthalates are a family of industrial compounds with a common chemical structure, dialkyl 
 
 
 
 
2 
or alkyl/aryl esters of 1, 2-benzenedicarboxylic acid.  Phthalates are primarily used to 
increase the flexibility, transparency, durability and longevity of plastics (15, 16).  As 
additives, phthalates are not covalently bound to plastic polymers.  Because phthalates easily 
leach from their matrix into the soil and water, and eventually gas off into the air, it is 
possible for phthalates to easily enter into the food chain (15, 16).  Worldwide, more than 8.2 
million tons of phthalates are used every year.  Di-(2-ethylhexyl) phthalate (DEHP) is the 
most commonly used in manufacturing. It is estimated that 2 million tons of DEHP is 
produced each year (15-19).   
Numerous biological effects have been attributed to phthalates.  Phthalates have been 
found to cause embryo toxicity, teratogenicity, developmental anomalies, and reproductive 
toxicity in animals (20-23).  Phthalates, particularly di-n-butyl phthalate (DBP) and DEHP have 
been more likely to cause reproductive toxicity and developmental abnormalities in animals (23-
26).  Anti-androgenic effects, such as short anogenital distance (AGD), cryptorchidism, 
decreased testosterone levels and decreased sperm production have been reported after exposure 
in-utero (23-26).  DEHP and its bioactive metabolite, mono-(2-ethylhexyl) phthalate (MEHP), 
prolonged the estrous cycle, inhibited ovulation and decreased systemic estradiol concentration 
in cycling rats, and were thereby considered to elicit toxic effects in the ovary (27, 28).  
Phthalates have also been considered as obesogens (29).  Mechanisms for phthalate-induced 
obesity include activation of peroxisome proliferator-activated receptors (PPARs), anti-thyroid 
activity, and anti-androgenic activity.  Childhood obesity has been linked with low dose 
exposure, particularly during fetal life (29).  
Most research about the biological effects of phthalates has been conducted in animal 
models; there have been few studies regarding human effects.  Evidence for reproductive 
dysfunction in animals following exposure to BPA is available, but human studies are limited.  
In laboratory animals, prenatal exposure to BPA at doses consistent with human environmental 
exposure has been associated with inhibition of folliculogenesis and ovulation, recurrent 
miscarriage, ovarian cysts, oviductal lesions, endometrial hyperplasia, uterine polyps, cervical 
sarcoma, mammary adenocarcinoma and changes in adult brain structure, chemistry and 
behavior (5, 10, 30).  In animals, BPA has been active as both an agonist and a competitive 
inhibitor of endogenous estrogen receptors, and as an antagonist of androgen receptors (31-34).  
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Both BPA and phthalates have been shown to affect reproduction in many animal studies.  
Similar research to investigate the reproductive health risks in men and women has been sparse. 
Prenatal exposure to BPA has been implicated as a cause of impaired fetal testicular function and 
a decrease in local androgen production in men as evidenced by the development of a short AGD 
and incomplete testicular descent (35).  In addition, correlations between urinary phthalate 
metabolites, abnormal semen quality and decreased steroid hormone levels in men have been 
reported (15, 36-38).  Metabolites of phthalates and BPA have been detected in human body 
fluids such as urine, serum, breast milk, saliva, sweat, ovarian follicular fluid (FF), seminal 
plasma (SP), peritoneal fluid and amniotic fluid (AF) (3, 39-48).  Greater concentrations of BPA 
and phthalates and/or their metabolites were detected in men and women with reproductive 
dysfunction compared to fertile men and women (18, 39, 49); however, continued research is 
required to confirm these preliminary findings.  
A decline in reproductive health has been observed in men and women within 
industrialized countries; the reasons for the decline are not well known.  The worrisome changes 
have been demonstrated by a greater frequency of abnormal semen parameters, infertility and 
testicular cancer in men; an increased incidence of congenital abnormalities of the reproductive 
tract in both men and women; and a decline in the pregnancy and birth rates, ovarian 
dysfunction, and an early onset of puberty and menopause in women (50-54).  The current 
prevalence of infertility in Canada ranges from 11.5% to 15.7%, and is similar to that of other 
industrialized countries (55, 56).  The underlying pathophysiology for many etiologies of 
infertility is not fully understood.  Infertility is diagnosed when a couple fails to conceive within 
12 months.  Unexplained infertility is diagnosed in 15%-30% of infertile couples when there is 
no identifiable cause.  Because of the association between reproductive dysfunction in animals 
exposed to EDC, there has been concern that EDC are the causal agents for infertility in humans.  
Research to elucidate the potential effects of EDCs, in particular phthalates, on human 
reproductive health are needed.  Studies conducted to date have been limited by small samples 
sizes, differences in methodologies, and high background contamination levels leading to 
contradictory results and inconclusive findings.  There is paucity of research to investigate the 
relationship between phthalates and human fertility.  To date, there has been no study conducted 
to quantify phthalates in body fluids of men and women within Saskatchewan.  Data from a pilot 
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study in our lab have suggested that serum BPA concentration were greater in male and/or 
female partners of couples diagnosed with unexplained infertility compared to controls; 
similarly, phthalate concentrations in the cellular component of blood were greater in women 
with Polycystic Ovary Syndrome (PCOS) compared to fertile women (Baerwald et al., 
unpublished data).  Further investigations are needed to confirm these preliminary findings.   
In the following chapters, graduate research to compare phthalate concentrations in fertile 
versus infertile men and women is described.  A literature review has been completed to discuss 
male and female reproductive anatomy, histology, and physiology; reproductive dysfunction; 
physiochemical properties, toxicokinetics and toxicodynamic effects of EDCs (in animals and 
humans); as well as analytical methods for phthalates quantification.  The rationale and 
hypothesis for the proposed research are followed by the study methodology, results and 
conclusions. 
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CHAPTER 2: LITERATURE REVIEW 
2.1 Human Reproductive Anatomy 
2.1.1 Female Reproductive System 
The female reproductive system consists of internal reproductive organs including the 
uterus, ovaries (female gonads), fallopian tubes (oviducts/uterine tubes), and external 
reproductive organs including the vagina and pudendum.  More detailed descriptions of the 
reproductive organs are included below.   
2.1.1.1 Ovaries 
 The ovaries are the female gonads. The ovaries are situated on either side of the uterus in 
the ovarian fossa of the female pelvis (57).  During embryonic development the ovaries form 
alongside the primitive kidneys at the thoracic level and descend to the brim of the pelvic cavity 
by the third month of intrauterine life.  A number of ligaments maintain the position of each of 
the ovaries.  The mesovarium is a double fold of parietal peritoneum connecting each ovary to 
the right and left sides of the uterus (medially) and to the pelvic walls (laterally).  The medial 
connector between the uterus and the ovary is called the ovarian ligament. The suspensory 
ligament is the lateral anchor of each ovary to the pelvic wall.  Each of the ovaries is comprised 
of four parts, from outer to inner: 1) the germinal epithelium, a layer of cuboidal epithelium 
covering the surface of the ovary; 2) the tunica albuginea, a dense connective tissue layer; 3) the 
cortex, the outer connective tissue layer containing the different stages of growing follicles; and 
4) the medulla, the inner connective tissue layer containing the blood vessels, nerves, smooth 
muscles, and lymphatics (57).  The ovarian hilum is the space through which blood vessels and 
nerves enter and exit the ovary. 
The blood-follicle barrier (BFB) is found within developing follicles of the mammalian 
ovary.  The barrier separates the avascular granulosa cell layer from the vascular thecal cell layer 
that surrounds each follicle.  The barrier is comprised of tight junctions between endothelial cells 
of the capillaries and the basement membrane of granulosa cells of the developing follicles (58).  
The BFB alters its composition rapidly during follicle development; changes in both size and 
charge selectivity occur (59, 60).  The barrier acts as a molecular sieve to create a specialized 
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environment within growing follicles.  The transfer of serum proteins from the blood into 
follicles during follicular development is regulated by the BFB (60, 61). 
2.1.1.2 Uterus and Cervix 
The uterus has many functions as a reproductive organ.  The uterus transports sperm from 
the vagina to the uterine tube, and is the site of embryonic implantation, fetal development, and 
parturition (57).  Anatomically, the uterus has three parts from upper to lower: 1) the fundus, the 
upper dome shaped part above the uterine cavity; 2) the body with a tapering central portion with 
a triangular cavity; and 3) the cervix, the lower tubular portion which connects the uterus to the 
vagina (57).  Histologically, the uterus has three layers from outer to inner: 1) the perimetrium, a 
part of visceral peritoneum forming a vesico-uterine pouch anteriorly and recto-uterine pouch 
posteriorly; 2) the myometrium, consisting of a middle circular and outer and inner longitudinal 
smooth muscles fibers; and 3) the endometrium, containing an epithelium, stroma, and glands 
(57).  Endometrium is arranged in two layers.  The inner most layer of the endometrium is the 
stratum functionalis, which undergoes proliferation and loss via menstruation.  The deeper layer 
of endometrium is called the stratum basalis.  The basal layer of endometrium is maintained 
during menses and regenerates the functional layer following menses (62, 63).  During 
embryological development, the Müllerian ducts gives rise to bilateral fallopian tubes, a single 
uterus and upper vagina. 
2.1.1.3 Fallopian Tubes 
A fallopian tube (also referred to as oviduct) extends from the right and left horns of the 
uterus to each ovary.  The function of the oviducts is to facilitate the transport of sperm to ovum 
and embryo to uterus (57).  Each oviduct is approximately 10 cm in length and has three parts 
from medial to lateral: 1) isthmus extends from the uterine horn to the ampulla; 2) ampulla, the 
the usual site for fertilization; and 3) infundibulum, contains fimbriae distally which assist with 
transport of the ovum from the ovary into the oviduct for fertilization (57).   
2.1.2 The Male Reproductive System 
The male reproductive system consists of internal and external genital organs.  The 
internal genital organs are: 1) the testes, which produce sperm and secret male sex hormones; 2) 
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the duct system including the epididymis, ductus deferens, ejaculatory duct  and urethra, which 
are required for the storage, maturation, and transport of sperm; and 3) the accessory sex glands 
including the seminal vesicles, prostate, and bulbourethral glands, whose secretions contribute to 
semen (57).  The external genital organs are: 1) the scrotum, which provides support for the 
testes and maintains the temperature for spermatogenesis; and 2) the penis, that delivers sperm 
into the female vagina (57). 
2.1.2.1 Testes  
 The testes are the primary reproductive organs. Histologically, each testis consists of the 
following layers from outer to inner: 1) tunica vaginalis, the outer peritoneal layer; 2) tunica 
albuginea, the inner visceral peritoneal layer that divides the testis into 200-300 lobules; 3) 
parenchyma, which consists of the seminiferous tubules (ST), interstitial cells of Leydig, 
connective tissue, capillaries and lymphatic vessels; and 4) hilum, a space which accommodates 
the rete testes, an anastomosing network of delicate collecting tubules (57).  Tight junctions 
between adjacent sertoli cells and peritubular capillary endothelial cells surround the ST to create 
the blood-testis barrier (BTB).  The BTB is designed to prevent destruction of the developing 
germ cells by harmful substances such as antigens, antibodies, and environmental toxins (64, 
65).   
2.2 Human Reproductive Physiology 
2.2.1 Female Reproduction 
 Female reproductive physiology involves ovarian and uterine cycles, which are highly 
coordinated.  The main function of the ovary is to cyclically release oocytes (i.e., eggs) and 
produce steroid hormones through the processes of follicle growth, maturation and ovulation 
(57).  Ovulation is the release of the oocyte from a preovulatory follicle into the peritoneal 
cavity.  The oocyte is taken up into the fallopian tube for fertilization.  Following ovulation, the 
follicle transforms into the corpus luteum (CL), a gland responsible for hormone production and 
maintaining early pregnancy. 
 In concert with the ovarian cycle, the uterine cycle involves proliferation and 
differentiation of the endometrium.  The menstrual cycle is under the influence of cyclic changes 
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in ovarian hormones.  The endometrium develops in preparation for implantation of an embryo.  
In the absence of pregnancy, ovarian hormonal support of the endometrium is withdrawn and 
dissolution of the endometrium culminates in menstruation.  The endometrial layers slough off 
during menstruation and the cycle ends.  The length of each menstrual cycle varies from 23-35 
days and averages 28 days.   
2.2.1.1 The Ovarian Cycle 
2.2.1.1.1 Follicular Dynamics 
Folliculogenesis is the process of growth, maturation and regression of follicles within 
the ovaries.  This process starts at approximately 24 weeks of gestation and ends at menopause 
(66, 67).  After initiation, the duration of follicular growth from primordial follicle stage to 
onwards takes approximately 175 days.  Folliculogenesis can be divided into pre-antral and 
antral stages.  The developmental transition from a resting state to a growing preantral follicle 
occurs over approximately 3 months (66, 67).  Development to a mature pre-ovulatory antral 
follicle occurs over the subsequent 85 days.  Pre-antral follicle development occurs independent 
of pituitary gonadotropins whereas antral follicle development is regulated, following puberty, 
by the cyclic production of gonadotropins (67, 68).  Pre-antral follicle development is divided 
into primordial, primary, and secondary stages.  Antral follicle development stages are described 
as early, mid, late and preovulatory. 
Folliculogenesis is preceded embryologically by the period of oogenesis, the formation of 
female gametes.  Between 4 to 6 weeks gestation, primordial germ cells (PGC) migrate from the 
dorsal wall of the yolk sac to the primitive indifferent gonadal ridge of the embryo (69, 70).  In 
the absence of male hormones, PGCs undergo mitotic division.  Differentiation of PGC into 
oogonia occurs with the onset of meiotic cell division.  Oogonia development is arrested at 
prophase-I of the first meiotic division; oocytes at this stage of growth are called primary oocytes 
(57).  Most oogonia undergo degeneration at early stages of development, contributing to 
depletion of the ovarian reserve.  Primary oocytes remain arrested at diplotene stage of meiosis I 
until the onset of puberty, at which time gonadotropic hormone production mediates the cyclic 
process of folliculogenesis (57).  At the time of ovulation, the primary oocyte completes the 
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second meiotic division, and is termed a secondary oocyte.  The second meiotic division is 
completed at the time of fertilization.   
2.2.1.1.1.1 Pre-antral Folliculogenesis 
Pre-antral follicle development involves the transition from primary to secondary and 
early tertiary follicles.  Stages of folliculogenesis are identified by the number of layers of 
granulosa cells, development of theca cells and the appearance of fluid filled cavity (antrum) 
(68).  At the beginning of pre-antral development, primordial follicles are approximately 35-38 
µm in diameter and contain a single layer of squamous-derived granulosa cells around the 
primary oocyte (71).  The mechanism underlying the initiation of primordial follicle growth and 
development is not well understood (71).  Primordial follicles develop into primary follicles 
measuring approximately 46µm in diameter, which contain a single layer of cuboidal granulosa 
cells.  At the primary follicle stage, a mucopolysaccharide membrane called the zona pellucida 
surrounds the oocyte (57, 72).  Primary follicles develop into secondary follicles, which are 80-
100 µm in diameter and contain two or more layers of granulosa cells with an independent blood 
supply (67).  Secondary follicles begin to express follicle stimulating hormone (FSH), estradiol 
(E2) and androgen receptors (AR) (67).  As the follicle enlarges, ovarian stromal tissues also 
stratify and differentiate into theca externa and interna.  Preantral follicles (150 µm) contain a 
steroid secreting theca interna layer.  Preantral follicles are sensitive to gonadotropins; however, 
their growth and development is thought to be mediated mainly by oocyte-derived factors (i.e., 
growth differentiation factor-9 (GDF-9), bone morphogenetic protein-15 (BMP-15), and 
granulosa cell-derived factors (i.e., anti mullerian hormone) (73-76).   
2.2.1.1.1.2 Antral Folliculogenesis 
The later stages of folliculogenesis include the development of early antral, antral and 
preovulatory (also known as “Graafian”) follicles.  The antrum is a fluid-filled cavity that 
develops within the follicle (67, 71, 77).  Early antral follicles are approximately 0.2 to 2 mm in 
diameter.  Cyclic recruitment of early antral follicles begins at the time of puberty when the 
hypothalamic-pituitary-ovarian axis is activated.  Antral follicles of 2-5 mm size can be detected 
ultrasonographically or histologically at any stage of the menstrual cycle during reproductive life 
(77-79).  Antral follicles are dependent upon gonadotropins for growth and ovulation.   
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Follicular Recruitment: Follicular recruitment (also referred to as “wave emergence”) is 
defined as the synchronous growth of a group or cohort of antral follicles.  The pattern of 
cyclical follicular recruitment has been debated for a long time (78, 80, 81).  Three different 
theories of follicular recruitment have been proposed: 1) continuous recruitment throughout 
reproductive life (82-84); 2) recruitment of a single cohort of antral follicles during the late luteal 
or early follicular phase (84, 85); and 3) recruitment of two or more waves of antral follicles in 
each menstrual cycle (78, 84, 86, 87).  Because antral follicular waves have been observed in 
animal species and women, the wave theory has emerged as the most acceptable theory to date.  
Two and three waves of follicles have been demonstrated in menstrual cycles of women at all 
reproductive ages (88).  The length of the menstrual cycle has been positively associated with the 
number of waves that developed (88).  Follicle waves have been described as either major or 
minor.  Major waves are those in which a single “dominant” follicle is selected for preferential 
growth.  A dominant follicle within a major wave may continue growth and development to 
ovulation or may regress as an anovulatory follicle.  Minor waves are those in which a dominant 
follicle is not selected (84).  A rise in FSH is thought to induce the emergence of each follicular 
wave. 
Ovarian follicular wave dynamics are studied over an interovulatory interval (IOI) rather 
than a menstrual cycle, in order to maintain methodological consistency among animal and 
human studies.  An IOI is the period from one ovulation to the subsequent ovulation; it is 
comprised of one luteal phase followed by one follicular phase.  Thus, an IOI is an inverted 
menstrual cycle.  In women of reproductive age, the final wave of an IOI occurs within the 
follicular phase and culminates with ovulation (termed a major ovulatory wave).  All preceding 
waves are either major or minor anovulatory waves (84).  The length of the IOI has been 
positively correlated with the number of waves that develop (88).  The luteal phase major wave 
illustrated in Figure 2.2.1 occurs in approximately 15% of women with 2-wave patterns of 
follicle development (78, 84).  Luteal phase major waves (i.e., major-minor-major or major-
major-major) occur in approximately 38% of women with 3-wave patterns of follicle 
development (Figure 2.2.2) (78, 84).   
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Figure 2.2.1:  Antral folliculogenesis and corresponding changes in reproductive hormones 
during 2 waves of follicle development.  Two waves of follicle development 
occur in approximately 68% of reproductive-aged women.  One menstrual cycle 
is represented by a follicular phase and a luteal phase.  One full interovulatory 
interval (IOI) is comprised of one luteal phase and one follicular phase.  Dotted 
vertical lines indicate wave emergence.  Used with permission from Blackwell 
Publishing Ltd., Human Reproduction Update, 2012 (84). 
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Figure 2.2.2:  Antral folliculogenesis and corresponding changes in reproductive hormones 
during 3 waves of follicle development.  Three waves of follicle development 
occur in approximately 32% of reproductive-aged women.  One full menstrual 
cycle (i.e. the follicular phase and luteal phase) and one full IOI (i.e. the luteal 
phase and follicular phase) are shown.  Dotted vertical lines indicate wave 
emergence.  Used with permission from Blackwell Publishing Ltd., Human 
Reproduction Update, 2012 (84).   
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Follicle Selection: Selection of a dominant follicle is described as the preferential growth 
of a follicle from a wave of growing follicles.  Within a given major wave, a single follicle is 
typically selected.  However, in some waves (especially in women during the transition to 
menopause) more than one dominant follicle may be selected (89).  The number of dominant 
follicles selected appears to depend upon the duration of rise of FSH, referred to as the “FSH 
window” (84).  Non dominant follicles within a wave are termed “subordinate” follicles (84, 90). 
 The growth of dominant follicles is highly dependent upon hormone production.  Inhibin 
B is produced by all follicles within a wave.  Inhibin B exerts negative feedback on FSH 
secretion from the anterior pituitary (91-93).  Selection of the dominant follicle occurs following 
a shift from FSH to luteinizing hormone (LH) receptor expression on granulosa cells.  At the 
time of selection, the dominant follicle expresses aromatase and produces 17-B estradiol.  
Subordinate follicles, in contrast, are androgenic.  The dominant follicle has been shown to 
contribute 90% of systemic estradiol during the mid-late follicular phase of the human menstrual 
cycle (94).  Secretion of insulin-like growth factor-1 and inhibin A also facilitate preferential 
growth of the dominant follicle in the mid-late follicular phase (95-97).   
Preovulatory Growth and Ovulation: The dominant follicle undergoes accelerated 
growth at a rate of 1-4 mm/day prior to ovulation (67, 78, 95).  A preovulatory follicle attains a 
diameter of 16-28 mm.  Preovulatory follicle growth is regulated by LH, inhibin A, and oocyte-
derived growth factors, such as GDF-9, BMP-15 and BMP-6 (76, 98, 99).  In the late follicular 
phase, estradiol from the dominant follicle provides positive feedback to the hypothalamus and 
pituitary to induce an LH surge (93).  The LH surge is the stimulus for ovulation.  The LH surge 
induces the primary oocyte to complete meiosis-I to become a secondary oocyte (93).  Ovulation 
occurs approximately 36 hours following the onset of the LH surge (100).  
In addition to inducing oocyte maturation, the LH surge stimulates a cascade of reactions 
within the preovulatory follicle.  LH induces granulosa cell prostaglandin E2 and F2α production, 
which increases blood flow in the preovulatory follicle (89, 100).  Luteinizing hormone 
stimulates the release of histamine in the preeovulatory follicle, which increases capillary 
permeability in the follicle wall (101).  Vasodilation and increased capillary permeability result 
in an increase in intrafollicular pressure.  The LH surge also induces proteolytic enzymes that 
degrade the follicular wall (100, 102).  Breakdown of the tunica albuginea and the supporting 
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epithelial basement membrane result in expansion of the granulosa cells surrounding the oocyte  
and release of the oocyte into the follicular antrum (100, 102).  The process of cellular death 
within the wall of the preovulatory follicle includes both apoptosis and necrosis.  The apical wall 
of the preovulatory follicle thins while the intrafollicular pressure increases.  The ultimate result 
of the coordinated morphologic, physiologic and biochemical event is ovulation, the rupture of 
the pre-ovulatory follicle and release of the oocyte.  After ovulation, the oocyte is taken up by 
the fimbriae of the fallopian tube in anticipation of conception (61, 100).  Ovulation signals the 
onset of the luteal phase of the menstrual cycle. 
2.2.1.1.2 Luteal Dynamics:    
After ovulation, cells from the pre-ovulatory follicle undergo morphological and 
functional changes.  Granulosa cells of the preovulatory follicle transform into large cells called 
granulosa lutein cells.  Adjacent theca cells transform into small cells called theca lutein cells 
(103-105).  The granulosa and theca lutein cells comprise the corpus luteum.   
The luteal phase is characterized by luteal growth and regression as well as progesterone 
synthesis.  Both granulosa and theca lutein cells produce progesterone, and to a lesser extent 
estradiol, androgens and inhibin.  After ovulation, rapid vascularization of luteal cells contributes 
to increased endocrine hormone production (104).  LH stimulates the conversion of 
pregnenolone to progesterone in granulosa and theca lutein cells, through the activation of  3β-
hydroxysteroid dehydrogenase (3β-HSD) enzyme (106).  Granulosa lutein cells secrete both 
progesterone and estrogen (76, 107).  The diameter, vascularity and progesterone production of 
the CL peak around 7 days post ovulation in non-conception menstrual cycles.  Progesterone 
maintains the stability of endometrium and increases the glandular activity of endometrium to 
provide an environment supportive for implantation and conception.  The role of luteal estradiol 
production is not known. 
In the absence of conception, regression of the CL occurs during a process referred to as 
luteolysis (108).  Luteolysis begins approximately 6-7 days after ovulation.  Prostaglandin F2α 
(PG F2α), a vasoconstrictor produced by the CL, is the main trigger for the luteolysis (108, 109).  
PGF2α causes vasoconstriction and reduced blood flow to the CL.  Regression of the CL 
culminates in a decline in progesterone and estrogen secretion and regression of the luteal phase.  
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As progesterone decreases, the negative feedback exerted by progesterone and estrogen is 
withdrawn, FSH rises, and the next menstrual cycle begins (107, 110).  The reduction of 
progesterone and estradiol in luteal phase induces ischemic changes in the endometrium and 
sloughing of the endometrial lining during menses.   
2.2.1.2 The Uterine Cycle 
The uterus is an endocrine organ which responds to hormonal signals from the ovary 
throughout the menstrual cycle in order to prepare the uterus for potential pregnancy.  The cycle 
of endometrial growth and regression is discussed in the following main phases (62):  
1) Proliferative phase  
Increased estradiol secretion during the follicular phase stimulates growth and proliferation 
of the stratum functionalis layer.  Menstruation ceases as endometrial growth begins; 
endometrial growth peaks just prior to ovulation.  The thickness of the endometrium increases 
from approximately 0.5 mm after menses to at approximately 10-11 mm at ovulation (111).  
Estradiol stimulates mitotic activity, nuclear DNA and cytoplasmic RNA synthesis in the 
functional layer of the endometrium (112, 113).   
2) Secretory phase 
Endometrial proliferation ceases after ovulation.  Progesterone attenuates the action of 
estrogen and mediates the decrease of luteal cell mitosis and DNA synthesis in the endometrial 
glands (114, 115).  Endometrial glands become tortuous, the spiral vessels undergo exaggerated 
coiling, and glycoproteins and peptides are secreted into the endometrial cavity.  The peak 
secretory changes occur by approximately 7 days after the onset of the LH surge in non-
conception cycles, and correspond with the timing for implantation. 
3) Menstrual endometrium 
After luteolysis, decreased progesterone and estradiol production results in endometrial 
ischemia, apoptosis, tissue loss and menstruation.  The stratum functionalis is shed during 
menses.  The stratum basalis is retained and participates in endometrial regeneration during the 
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next menstrual cycle.  Menstrual fluid is composed of autolysed stratum functionalis, 
inflammatory exudate, red blood cells, and proteolytic enzymes (116). 
2.2.2 Male Reproduction 
2.2.2.1 Spermatogenesis  
Primordial germ cells proliferate and differentiate into spermatogonia during embryogenesis.  
Roughly 300,000 spermatogonia in each gonad remain dormant during childhood.  By puberty, 
there are approximately 600,000,000 spermatogonia in each testis.  It has been estimated that 
following puberty 100-200 million sperm are produced each day (117).  Three phases of 
spermatogenesis take place in the seminiferous tubule:  
1) Spermatogonia undergo mitosis.  
2) Primary and secondary spermatocytes undergo meiosis I and II to ultimately produce 
haploid (1N) spermatids 
3) Spermatids undergo morphological differentiation into sperm through a process of 
spermiogenesis (118).   
The complete process of spermatogenesis takes approximately 70 days in humans (119).  An 
additional 12-21 days are required for sperm to travel through the epididymis in order to be 
ejaculated through the vas deferens (120, 121).  The actions of both Sertoli and Leydig cells are 
needed for spermatogenesis. 
Sertoli cells are comparable to the granulosa cells of ovarian follicles with respect to the 
cells’ supportive function for male gametes.  Sertoli cells extend from the basement membrane 
of the epithelium of seminiferous tubule to the apical lumen.  Sertoli cells support and protect the 
developing spermatogenic cells.  Sertoli cells secrete androgen binding protein, which binds 
testosterone and maintains it at high concentrations within the testes.  The inhibin, secreted by 
Sertoli cells, suppresses FSH secretion from the anterior pituitary.  Sertoli cells secrete fluid 
necessary for sperm transport. 
Clusters of Leydig cells are located between adjacent seminiferous tubules.  LH secreted 
from the anterior pituitary induces testosterone secretion from the Leydig cells (Figure 2.2.3).  
Testosterone is converted to dihydrotestosterone (DHT) by 5α-reductase in the Sertoli cell (118).  
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DHT is the biologically active form of testosterone.  During embryonic development, 
testosterone stimulates differentiation of the Wolffian ducts into the vas deferens, epididymis and 
seminal vesicles, and promotes descent of the testicles into the scrotum.  After conversion of 
testosterone to DHT, fetal external genitalia become virilized.  At puberty, DHT induces 
enlargement of the male external and internal sex organs, as well as secondary male sexual 
characteristics (122). 
2.2.3 Regulation of Hormone Production 
The hypothalamo-pituitary-gonadal (HPG) axis plays a fundamental role in regulation of 
both male and female reproductive function.  The gonads and anterior pituitary produce 
hormones and growth factors to regulate steroid hormone production in both men and women 
(Figure 2.2.4).  The hormones provide positive and negative feedback to the pituitary and 
hypothalamus and affect hormone synthesis and secretion.   
  The HPG axis is thought to be activated temporarily during early stages of fetal 
developmental and then reactivated at the time of puberty.  During reproductive life, 
gonadotropin releasing hormone (GnRH) is secreted from the arcuate and preoptic nuclei of the 
hypothalamus in a pulsatile manner (123).  GnRH travels via the hypophyseal portal system into 
the anterior pituitary where it stimulates gonadotroph cells to secret the gonadotropins (i.e., FSH 
and LH) (124).  While slow GnRH pulse frequency stimulates FSH synthesis, fast GnRH pulse 
frequency induces LH synthesis (125).  FSH and LH bind to receptors within the ovary and testis 
to induce steroid production and gametogenesis.   
2.2.4.1 Male Reproduction  
The male HPG axis involves the hypothalamus, pituitary and testes (Figure 2.2.4).  
During fetal life and childhood, the release of GnRH from the hypothalamus is suppressed by an 
ultrasensitive negative feedback of testosterone and estradiol from the testes (126).  At the onset 
of puberty there is decreased sensitivity of the hypothalamus to this negative feedback.  After the 
onset of puberty, GnRH is released in a pulsatile fashion by the hypothalamus and LH and FSH 
are secreted by the pituitary every 2-6 hours totaling 4-8 times /day.  Gonadotropin release is 
followed by testosterone secretion from the testis (126).  LH binds to receptors on Leydig cells 
of the testes to stimulate the conversion of cholesterol to progesterone to testosterone.  
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Testosterone crosses the blood testes barrier, enters the Sertoli cells and is converted to DHT 
(and to a lesser degree, estrogen).  FSH binds to receptors on Sertoli cells to induce the 
production of androgen-binding protein and inhibin-B.  Because androgen binding protein binds 
testosterone, a high concentration of testosterone is maintained in the testes.  Testosterone can 
then induce spermatogenesis in the testes.  Inhibin-B provides negative feedback to the anterior 
pituitary to suppress FSH secretion (118, 124).  Following inhibin-B mediated negative 
feedback, the LH amplitude is greater than that of FSH (126).  Testosterone, DHT and estradiol 
from the testes also provide negative feedback control on the hypothalamus and pituitary (127). 
2.2.4.2 Female Reproduction   
 The female HPG axis involves the hypothalamus, pituitary and ovaries (Figure 2.2.4).  
Before puberty, GnRH is secreted at low amplitude and low frequency from both tonic and surge 
centers in the hypothalamus.  Low amplitude GnRH secretion is insufficient  to stimulate the 
anterior pituitary to produce LH and FSH (126).  In the prepubertal ovary, estradiol is produced 
at a level below the threshold level required to stimulate the estrogen sensitive surge center.  
After puberty onset, the tonic center is responsible for the basal secretion of GnRH.  The surge 
center controls the large preovulatory surge of GnRH and the surge of LH by the pituitary.  LH 
binds to receptors on theca cells located alongside follicles to stimulate the stepwise conversion 
of cholesterol to progesterone to androstenedione (Figure 2.2.3).  Androstenedione moves from 
the theca cells, crosses the blood-follicle barrier and travels to the granulosa cells.  FSH binds to 
its receptors on the granulosa cells and induces the conversion of androstenedione to estrone and 
testosterone to estradiol. 
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Figure 2.2.3: The 2 cell 2 gonadotropin theory of male and female reproductive function. In 
men, the conversion of cholesterol to testosterone takes place in Leydig cells of 
the testes.  Testosterone migrates across the blood testes barrier into the Sertoli 
cells to induce spermatogenesis. In women, androgens are produced in the theca 
interna cells of growing follicles, and migrate across the blood-follicle barrier 
into the granulosa cells where they are converted to estradiol (From Baerwald 
2005, unpublished). 
  
Cyclic changes in gonadotropins regulate menstrual cyclicity.  During the mid-follicular 
phase, inhibin B is produced by the granulosa cells of all follicles of the wave.  The rising inhibin 
B directly inhibits the pituitary secretion of FSH (91, 92).  It is thought that follicles continue to 
undergo atresia under the influence of declining FSH until only a single dominant follicle 
remains for continued growth (128).  In the late follicular phase, a high concentration of 
estradiol, secreted by the dominant follicle granulosa cells, exerts positive feedback to the 
hypothalamus to induce the LH surge prior to ovulation (89, 129).  During the luteal phase of the 
menstrual cycle, progesterone and estradiol from the CL provide negative feedback to the 
pituitary to suppress all but basal FSH and LH production.  With regression of the CL, luteal 
phase progesterone and estradiol production decreases, FSH rises and the next menstrual cycle 
begins (82, 110). 
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Figure 2.2.4:  The hypothalamo-pituitary-gonadal axis in men and women. Gonadotropin 
releasing hormone (GnRH) regulates the secretion of gonadotropins (FSH and 
LH) from the anterior pituitary, and thereby stimulates the gonads (ovaries and 
testes) to produce steroid hormones. Steroid hormones provide negative (-) 
and/or positive (+) feedbacks at the level of hypothalamus and/or pituitary. 
 
2.3 Reproductive Dysfunction  
 Many etiologies of reproductive dysfunction have been described.  Approximately 1 in 6 
couples experience infertility at some time in their lives (130).  Infertility is defined as  the 
inability to achieve pregnancy after one year of reasonably regular unprotected sexual 
intercourse (131).  “Subfertility” is used to describe decreased reproductive efficiency without 
sterility (131).  Infertility gives rise to a great deal of medical, psychosocial and economical 
stress for patients.  Infertility can be considered primary and secondary.  In primary infertility, 
women/couples have never conceived, whereas secondary infertility occurs after proven fertility.  
The etiology of infertility is roughly accounted for by male factor dysfunction in 1/3 of all 
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couples, female factor dysfunction in1/3, and combined male and female dysfunction in the 
remaining 1/3 (132).  
2.3.1 Female Infertility  
A dramatic change in female fertility has been observed over the past 30 years.  The peak 
age for fertility in women is between 20 and 24 years; a progressive decrease in cycle fecundity 
occurs with age.  The cumulative decline in fertility has been estimated to be 4-8% at 25-29 
years; 15-19% at 30-34 years; 26-46% at 35-39 years; and 95% by 40-45 years (131,133, 134). 
Completion of advanced education, economic reasons for women to take on careers, delayed age 
at marriage and child bearing, and easy access to family planning services are socioeconomic 
factors that have contributed to a decline in both female fertility and birth rate in North America 
(131).  Infertility may occur solely because of conditions borne by women such as ovulatory 
dysfunction (40%) as well as tubal and pelvic pathology (40%).  “Other” miscellaneous 
etiologies are found in approximately 10% of women; “other” etiologies may be attributed to 
uterine, cervical and vaginal etiologies, advanced age, extremes of weight, smoking, excessive 
alcohol or drug use, occupational or environmental exposure to contaminants, and stress (131). 
Infertility is unexplained in 10-25% of couples.  
2.3.1.1 Ovulatory dysfunction    
 Ovulatory disorders are one of the major reasons for female infertility.  Ovulatory failure 
(anovulation) and infrequent ovulation (oligoovulation) are the most common presentations. 
Polycystic ovarian syndrome (PCOS) is a very common endocrine and metabolic disorder (135-
137).  Approximately 1.4 million Canadian women (12%) are diagnosed with PCOS (137, 138).  
Polycystic ovarian syndrome is a major cause of hormone imbalance, anovulatory infertility and 
miscarriage (136, 139-141).  A spectrum of symptoms are seen and no single diagnostic criteria 
for PCOS has been identified (141, 142).  The major clinical manifestations of PCOS include 
weight gain with central obesity, irregular and infrequent menstruation, male pattern hair 
distribution, acne, insulin resistance manifested as acanthosis nigricans, and mood disorders 
(139, 140).  The diagnosis of PCOS requires at least two of the following three criteria: 1) 
irregular or absent menstruation (>35 days), 2) clinical and/or biochemical signs of high 
androgen hormone and 3) polycystic ovaries as seen ultrasonographically with exclusion of other 
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endocrine disorders of the adrenal, thyroid, pituitary and hypothalamus (139, 140, 142). 
Ultrasonographic diagnostic criterion for PCOS includes > 26 antral follicles per ovary (143). 
The pathogenesis of PCOS is uncertain.  A combination of genetically inherited 
mutations (e.g., cytochrome P450c19 aromatase gene and TAAA repeats in SHBG promoter) 
and environmental factors may lead to excess androgen exposure during the critical intrauterine 
period of organogenesis (144).  A fetal origin for PCOS has been proposed in rats. Fetal rats 
exposed to a high androgenic environment in utero expressed a PCOS phenotype and metabolic 
alterations later in adult life (145, 146).  These studies have supported the concept that in utero 
exposure to a high androgenic environment may contribute to epigenetic abnormalities 
underlying the fetal origin and inheritance of PCOS.  In women, systemic hormonal imbalances 
in classic PCOS include elevated LH, low FSH/LH ratio, excess androgens, low normal estradiol 
level without cyclic variability and high insulin (147).  It is thought that insulin resistance results 
in greater synthesis of testosterone within the ovaries, greater production of androgens from the 
adrenal glands and less formation of sex hormone binding globulin (SHBG) from the liver (148).  
Peripheral conversion of androgens to estrogens in fat, liver, and muscle leads to low FSH and 
prevents follicle growth and ovulation (149, 150).  Long term complications of PCOS include 
miscarriage, hyperlipidemia, hypertension, diabetes, cardiovascular disease and endometrial 
hyperplasia (139, 140, 151-153).     
Premature ovarian failure (POF) is an uncommon reason for anovulation.  Cessation of 
menstruation before the age of 40 with a low or absent ovarian antral follicle count is diagnostic 
of POF (154, 155).  Causes of POF are most often unknown (155).  The etiology may be 
acquired or may be of genetic origin.  Acquired causes include chemotherapy, radiotherapy, 
surgery, autoimmune disease, infection, smoking and exposure to toxins.  Genetic disorders 
involving the X chromosome (i.e., 45XO karyotype) have been seen in women with POF (156). 
Many endocrine disorders are associated with anovulation and oligoovulation.  Thyroid 
disease including hyper and hypothyroidism and hyperprolactinemia may culminate in 
anovulation (131).  Adult onset congenital adrenal hyperplasia mimics PCOS as an uncommon 
reason for anovulation, androgen excess and hirsutism (157).  Pituitary hypersecretion of 
prolactin may occur following the development of a pituitary adenoma or brain tumor or with 
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ingestion of specific medications (158).  Physical and emotional stress has been associated with 
suppression of hypothalamic activity.  
2.3.1.2 Tubal and pelvic factors  
Acquired abnormalities of the reproductive organs are one of the most common reasons 
for infertility in women.  Tubal infertility is diagnosed when the fallopian tube is congenitally 
abnormal or when the oviducts are structurally damaged or surgically removed (131).  The most 
common causes of tubal infertility are obstructive processes including pelvic endometriosis, 
pelvic inflammatory disease, septic abortion, ectopic pregnancy, ovarian torsion and bowel 
infections such as ruptured appendicitis.  Tubal ligation surgery causes infertility for 
contraceptive purposes.  
2.3.1.3 Unexplained infertility  
Unexplained infertility is a difficult and disconcerting diagnosis for couples.  
Unexplained infertility is defined by the absence of an identifiable reason for infertility.  In 
approximately one quarter to one-third of couples, the cause of infertility is unexplained.  A 
diagnosis of unexplained infertility is made when a couple fails to conceive within 1 year of 
unprotected intercourse, and all conventional diagnostic tests or methods to detect the etiology of 
infertility (e.g., ovulation testing, ovarian reserve, semen analysis, anatomic imaging) are normal 
(131, 159, 160).  Abnormalities in fertilization or implantation may be observed during in vitro 
fertilization.  Currently, no predictors for aberrant fertilization or implantation exist (161).  
Immunological, genetic, endocrinological and environmental factors have been proposed as 
potential causes of unexplained infertility (161-164).   
2.3.1.4 Other factors   
Other less common etiologies for female infertility have been identified.  Congenital 
abnormalities of the uterus such as a uterine septum have been associated with recurrent first 
trimester miscarriage and mid–late second trimester preterm delivery (165).  Other conditions 
that affect fertility include intrauterine adhesions (Asherman’s syndrome) (165), endometrial 
polyps, and fibroids.  Damage to the cervical canal following the growth of cervical fibroids, 
cervical surgery or sexually transmitted infections with chlamydia or gonorrhea may impair 
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sperm transport (131, 166).  Anti-sperm antibodies may cause infertility by directly destroying 
sperm (167).  Alterations of chemical signals within the HPG axis may result in infertility.  
Dysregulation of the HPG axis occurs with some disease conditions, such as hypothyroidism, 
hyperthyroidism, hyperprolactinemia and anorexia nervosa.  Additional factors, such as 
medications, psychological and environmental stressors may also lead to hormonal changes that 
affect the HPG (131).  Stress-mediated release of catecholamines (adrenaline, noradrenaline and 
dopamine) may interact with the release of GnRH, FSH, LH and prolactin production and 
interrupt follicle growth and ovulation (168). 
2.3.2 Male Infertility  
The etiology of infertility is attributed solely to the male partner in approximately 1/3 of 
couples.  Fertility status in men has been classified as fertile, subfertile and infertile based on 
semen parameters (169).  Infertility is considered to be of male origin when semen volume is <1 
mL, sperm concentration is < 2.0 x106/ml, progressive motility is <10%, or normal morphology 
is <5%.  Normal semen parameters are shown in Table 2.3.1.  Reproductive dysfunction in men 
has been divided into congenital, acquired and idiopathic etiologies.  The diagnosis is 
unexplained for 40-45% of men with infertility.  The known causes of male infertility include 
hypothalamic-pituitary disorders (1-2%), primary gonadal disorders (30-40%) and disorders of 
sperm transport (10-20%) (170).  Hypothalamic-pituitary disorders are related to infertility in 
patients with Kallmann syndrome, brain tumors, hyperprolactinemia, drug use, physical injury, 
brain infection, chronic systemic illness and obesity.  Primary gonadal disorders arise from 
congenital conditions, such as Klinefelter syndrome, deletion of Y chromosome, various genetic 
mutations, crytorchidism, or acquired conditions such as testicular infection.  Exposure to 
environmental toxins (e.g., smoking, metals, organic solvents and pesticides), drugs (e.g., 
alkylating agents, alcohol, antiandrogens and cimetidine), radiation, chronic systemic illnesses, 
and excessive heat may lead to testicular dysfunction and infertility.  Disorders of sperm 
transport are seen with congenital absence of the vas deferens, Kartagener syndrome (a defect of 
cilia), epididymal obstruction or dysfunction, and blockage of vas deferens by infection from 
gonorrhoea, chlamydia or tuberculosis, erectile or ejaculatory dysfunction or vasectomy (170).   
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Table 2.3.1: Normal semen parameters (modified from WHO 5th manual, 2009-10) (171). 
 
 
 
 
 
 
 
2.4 Endocrine Disrupting Chemicals:  Phthalates                     
Endocrine disrupting chemicals (EDCs) are a heterogeneous group of chemicals that 
mimic or interfere with the action of endogenous endocrine hormones.  EDCs encompass 
hundreds of chemicals, either natural or manmade.  Bisphenol A (BPA) and phthalates are 2 
groups of widely used synthetic EDCs.  
Phthalates, esters of phthalic acid, are used as plasticizers to impart flexibility, 
transparency and longevity to plastics.  Phthalates were first commercialized as plasticizers in the 
1920s.  Phthalates are widely used in personal care products, cosmetics, air fresheners, soft toys, 
paint, lubricants, adhesives, medical equipment, flooring, and many other products (16, 172-
175).  It is estimated that 18 billion pounds of phthalates are manufactured throughout the world 
annually (17, 19).  As phthalates are not covalently bound to polymers, they easily leach out of 
plastics into the environment (175, 176).  Phthalates enter the food chain from air, water, soil, 
and food containers/packaging.  Phthalates of potential health concern include: DBP, diisobutyl 
phthalate (DiBP), benzyl-butyl phthalate (BBP), butyl-benzyl phthalate (BBzP), di-n-pentyl 
phthalate (DnPP), DEHP, di-n-octyl phthalate (DnOP), diisononyl phthalate (DiNP) and 
diisodecyl phthalate (DIDP) (175).  DEHP and DBP have been the most widely used phthalates.  
DEHP is commonly used in the polyvinyl chloride (PVC) market for its stability, fluidity and 
low volatility (177).  Because of the widespread use of plastics, phthalate exposure is significant 
(15). 
Volume (ml) 1.5 
Sperm concentration (106/ml) 15 
Total sperm count (106) 39 
Motility (% progressive) 28 
Vitality (% live) 59 
Morphology (% normal) 3 
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2.4.1 Physical and Chemical Properties  
Phthalates are unique chemical compounds.  Phthalates are alkyl/aryl esters of 1, 2-
benzenedicarboxylic acid.  The basic chemical structure of phthalates involves a benzene ring 
attached to two carboxylic acids at carbon 1 and 2 positions of the benzene ring.  The carboxylic 
acids are attached with either a dialkyl or alkyl/aryl ester side chain.  Branching patterns and 
length of the dialkyl or alkyl/aryl side chains determine the molecular weight (i.e., high vs. low) 
and physiochemical properties of different phthalates.  The side chain also influences the chemo-
dynamics in the environment, as well as metabolism, toxicity and excretion of phthalates from 
the body (15, 177).  The physical and chemical properties of DEHP are shown in Table 2.4.1. 
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Table 2.4.1: Physical and chemical properties of DEHP (taken and modified from Agency for 
Toxic Substances and Disease Registry (ATSDR),Toxicological Profile for 
DEHP, 2002) (16) 
Properties     Value and Reference 
Molecular weight 390.7 (178) 
Color  Colorless (179) 
Physical state Liquid (177) 
Melting point 470C  (177) 
Boiling point 3840C  (178) 
Solubility: 
  Water 
  Organic 
 
Vary between 1.1-1200 µg/L (177) and 41 
µg/L(180) distilled water at 25 0C  
Solubilized  in mineral oil and hexane (180)  
Partition coefficients: 
  Log Kow 
  Log Koc 
 
7.50  (177) 
4.9-6  (177) 
Vapor pressure  1.0x10-7 mmHg at 250C  (177) 
Henry's law constant:  1.71x10-5 atm-m3/mole at 250C (177) 
Autoignition temperature  7350F  (390 0C)   (180)  
Flashpoint  3840F (196 0C) open cup (179)  
Flammability limits  No data  
Explosive limits  0.3% (lower limit)  (179) 
No data (upper limit)  
Conversion factor  
 
1 ppm=15.94 mg/m3  (181) 
2.4.2 Human Exposure to Phthalates 
Humans are widely exposed to phthalates in day to day life.  As additives, phthalates are 
not chemically bound to plastic polymers.  It is possible for phthalates to easily enter into the 
food chain because they leach from their matrix into the soil and water, and can be released 
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into the air (15, 16).  Human exposure is possible via oral, inhalation, dermal and parenteral 
routes (15, 16, 17, 29, 175, 182, 183).  Inhalation of phthalates in air particles and dust is a 
significant source of exposure (17, 184).  Exposure to high molecular weight (HMW) phthalates, 
such as DEHP and DiNP, occurs mainly through the oral route.  Soil has been a notable source of 
exposure to HMW phthalates for toddlers (184).  Patients who require artificial ventilation, 
dialysis, intravenous fluids and critical medical care are also exposed to DEHP via the parenteral 
route.  HMW phthalates are used to manufacture food packaging, building materials, and 
medical devices.  Exposure to low molecular weight phthalates, such as DEP and BBP, occurs 
mainly through the skin (15, 17, 173).  Low molecular weight (LMW) phthalates are used to 
produce personal care products (PCP), flooring, paints and adhesives.  According to the US 
Environmental Protection Agency (EPA), the reference doses (RfD) of DEHP, BBP, DBP and 
DEP have been 20, 200, 100 and 800 µg/kg/day, respectively (17, 184).  The daily intake of 
DEHP and DBP in the general population has been greater than other phthalates due to their 
widespread application (184). 
Possible external sources of phthalate exposure and proportional contributions from 
different sources have been investigated.  The summary of all potential sources of common 
phthalates are shown in Table 2.4.2.  The contributions from all possible food and environmental 
sources in China has been reported to be the following: air (43–50%), drinking water (24–34%), 
foodstuffs (19–24.5%), dust (3–5.5%) and soil (<0.2%) (184).  In the same study, the daily 
intakes (ng/kg body weight/day) of six phthalates were measured as: DBP (277–368), DEHP 
(149–203), DMP (dimethyl phthalate, 97–131), DEP (25–37), BBP (1.8–2.5), and DOP (1.5–2.1) 
(184).  The estimated daily exposure to DEHP (excluding other types of exposure, such as 
occupational, medical and non-dietary ingestions in children) was from 3-30 µg/kg body weight 
(17, 185).  Exposure to phthalates in children is higher than adults due to their frequent hand-to-
oral contact (185).  Children tend to be more susceptible to toxicity because of higher metabolic 
conversion to active metabolites and greater surface area to weight ratio compared to the adult 
(29, 185, 186).  Occupational and medical exposures to DEHP (e.g., dialysis, respiration therapy, 
blood transfusions, or total parenteral nutrition treatment) are considerably greater compared to 
daily exposures in the general population (17, 183).  Exposure has been estimated to be 700 µg 
/kg /day via inhalation in the plastics manufacturing workplace and 457 µg /kg /day for a patient 
undergoing dialysis or a blood transfusion (17, 183, 187).  Phthalate metabolites have been 
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detected in the urine of American residents at levels above the exposure detection limit.  It has 
been also reported that the number of PCP (e.g.,  soaps, body washes, shampoos, and cosmetics) 
used by adult women is associated with higher concentrations of certain urinary phthalate 
metabolites (172).  After exposure via the different routes, phthalates undergo absorption, 
distribution, metabolism and excretion from the body. 
 
Table 2.4.2:  Summary of all possible sources of exposure to common phthalates and observed 
adverse outcomes in animals (modified from Hauser et al., 2005) (15). 
Phthalates  Possible exposure sources Commonly observed health 
effects (in animals, at high doses) 
DEP Personal care products (e.g.,  fragrances), 
coatings, paintings, and pesticides 
Reduced growth rate, reduced food 
consumption, increased organ 
weight 
DnBP Cellulose acetate plastics, personal care 
products, repellants, polishes, 
pharmaceutical coatings 
Hepatic and renal effects, 
developmental and reproductive 
effects, decreased fetal weight 
BBP Vinyl flooring, adhesives and sealants, 
car care products, toys, food packaging, 
industrial solvents, PCPs (e.g., soaps 
fragrances, lotions, nail polishes) 
Testicular toxicity, cryptorchidism, 
short ano-genital distance, altered  
steroid hormone levels, teratogenic 
DEHP PVC plastics for domestic purposes, such 
as toys, floor, tiles, furniture, and wall 
painting, foods packaging; blood storage 
bags and other medical devices 
Hepatocellular carcinoma, testicular 
toxicity, anovulation, decreased 
fetal growth and teratogenesis at 
high doses 
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2.4.3 Toxicokinetics of Phthalates 
2.4.3.1 Absorption and Distribution 
Absorption and distribution of phthalates in mammals varies depending on the route of 
exposure.  Besides gastrointestinal absorption, phthalates can be absorbed through skin and lungs 
in both humans and rodents.  Absorption of phthalates is greater via the gut compared to the 
dermal route.  Interspecies differences in phthalate absorption have been explored (188).  
Absorption of DEHP from the gut has been shown to be lower in both humans and non-human 
primates compared to rodents.  This finding may be explained by knowledge that the bio-
activation enzymes are less active in non-human primates compared to rodents.  Absorption of 
phthalates via the gut may also vary depending on the exposure dose.  At low doses, DEHP is 
absorbed as one of the following two metabolites: mono (2-ethylhexyl) phthalate (MEHP) or 
mono (2-ethyl-5hydroxyhexyl) phthalate (MEHHP).  In contrast, at high doses, some parent 
DEHP can be absorbed (189).  Unhydrolyzed DEHP can be metabolized via non-specific 
esterases present in the blood and/ or tissues (16).  After oral administration, the estimated 
absorptions were as high as 25% in humans, >55% in rats, and <55% in non-human primates 
(190).  The absorption of DEHP via the human skin is very low, around 1.1% of a 24-hour 
dermal application (16).  After being absorbed, DEHP and its metabolites are distributed 
throughout the body via the blood.  In blood, approximately 80% of DEHP is bound to 
lipoproteins and the rest to albumin (189).  In rodents and monkeys given oral DEHP, the liver 
has been shown to contain the greatest concentration of DEHP and its metabolites (16).  The 
absorption and distribution of oral phthalates have not been well-characterized in humans.  The 
internal disposition of phthalates in the body has been shown to be falsely high (17).  The 
inaccuracy of measurement may have occurred because of contamination of biological samples 
during laboratory processing (15, 16).  Another factor that must be addressed during the 
assessment of phthalate absorption is the contribution that phthalate metabolism has upon the 
measures of absorbed phthalates. 
2.4.3.2 Metabolism and Excretion  
Phthalates are lipophilic, and hence undergo phase-1 and phase-II metabolic conversion 
in order to become water soluble.  Water soluble metabolites are readily excreted from the body.  
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Phthalates have short biological half-lives, metabolize quickly and do not accumulate.  
Metabolites of phthalates are primarily excreted in the urine and feces (15, 191) 
2.4.3.2.1 Phase-I Biotransformation 
In phase-I metabolism, phthalates are converted to bioactive monoesters.  Phase-I 
activation takes place in the gut, liver and blood.  The phase-I reaction involves hydrolysis of one 
of the ester bonds by hydrolytic enzymes, such as lipase or esterase. The monoesters of common 
phthalates are shown in Table 2.4.3.  Phase-I biotransformation is different for HMW and LMW 
phthalates.  For example, relatively polar and low molecular weight phthalates, such as DEP, are 
primarily metabolized into their hydrolytic monoesters.  In contrast, high molecular weight 
phthalates (e.g., DEHP and DIDP) undergo hydrolysis followed by further secondary oxidation 
of the side chain.  The result of phase-I oxidation reactions is the production of metabolites that 
are relatively more hydrophilic (15, 191).   
Table 2.4.3: The hydrolyzed phase-1 metabolites of four diester phthalates 
Parent diesters Primary monoesters 
BBzP, n-butylbenzyl phthalate MBzP, mono-benzyl phthalate 
DEP, diethyl phthalate MEP, mono-ethyl phthalate 
DEHP, di-(2-ethylhexyl) phthalate MEHP, mono-(2-ethylhexyl) phthalate 
DBP, di-n-butyl phthalate MBP, mono-n-butyl phthalate 
 
DEHP undergoes phase-1 hydrolysis and oxidation.  In phase-1 hydrolysis, DEHP 
converted to a bioactive metabolite, MEHP.  In phase-I oxidation MEHP undergoes several 
oxidation reactions and forms 30 secondary oxidized metabolites.  The main 4 secondary 
oxidized metabolites are: mono-(2-ethyl-5hydroxyhexyl) phthalate (MEHHP), mono-(2-ethyl-
5oxohexyl) phthalate (MEOHP), mono-[2-ethyl-5carboxypentyl] phthalate (5cx-MEPP) and 
mono-[2-(carboxymethyl)hexyl] phthalate (2cx-MMHP) (Table 2.4.4) (15, 191, 192).  It has 
been reported that 5cx-MEPP and 2cx-MMHP represent chronic exposure to DEHP because the 
elimination half-life is long (15, 192).  In contrast, MEHHP and MEOHP represent short-term 
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exposure (15, 192).  Phthalate monoesters and oxidative metabolites are excreted from the body 
directly without further metabolism.  For example, low molecular phthalates, such as DEP, are 
removed after phase-I hydrolysis mainly as free MEP in the urine.  Alternatively, excretion may 
occur after phase-II bio-transformation (15, 29, 189, 191-193).   
Table 2.4.4: The two-step phase-1 bio-transformation of DEHP  
Parent Diester Phase-1 hydrolyzed metabolites Phase-1 oxidative metabolites 
 
DEHP MEHP 
 
MEHHP, MEOHP, 5cx-MEPP and 
2cx-MMHP 
 
2.4.3.2.2 Phase II Biotransformation and Excretion 
 Phase-II biotransformation increases the water solubility of phase-I phthalate metabolites.  
Phase-II conversion occurs mainly in the liver.  The phase-II reaction involves addition of a 
glucuronic acid to the bioactive compound by enzymatic conjugation, such as glucuronidation.   
In human and non-human primates, DEHP metabolites (approximately 65%) are excreted 
predominantly through urine in the form of glucuronide conjugates (16).  Other metabolites of 
DEHP include free MEHP, oxidized metabolites and phthalic acids.  In rabbits, the 
unmetabolized/unabsorbed DEHP is excreted through feces.  Like DEHP, other high molecular 
weight phthalates (such as DiNP, DIDP and DnOP), are excreted as conjugated metabolites in 
the urine (15, 194, 195).  DBP is excreted via the urine in low concentrations as conjugated or 
unconjugated MnBP or various oxidation products of MnBP; and a small amount is excreted as 
free phthalic acid (174, 196).  Approximately 24 hours are needed to eliminate more than 50% or 
oral DEHP and 5-7 days are needed to excrete 80% of the total dose (188, 190, 197).  Most of 
absorbed DBP is excreted from the body within 24 hours, and virtually all is cleared within 48 
hours (174).  
The kinetics and fractional elimination of primary and secondary phthalate metabolites 
have also been investigated.  After a single oral dose of deuterated DEHP and DINP, urinary 
elimination was reported in the following order of magnitude: MEHHP>5cx-
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MEHP>MEOHP>MEHP (198).  More than 90% of the metabolites were eliminated via urine in 
the first 24 hours and the remaining metabolites were excreted in the next 24 hours.  The half-
lives of the metabolites were approximately 4-8 hours (198).  Stephen et al., (2012) quantified 
and compared phthalate diesters and metabolites between human serum, sweat and urine (48).  
Elimination of certain phthalate metabolites (particularly MEHP) occurred at a greater 
concentration in sweat than in urine.  In several participants, detection of DEHP in sweat 
exceeded that in blood sera; differential levels supported the concept of tissue bioaccumulation 
of phthalates (48).  As phthalates are lipophilic, they tend to accumulate in the adipose tissue.  
Further research is needed to measure and compare phthalate concentrations among blood serum, 
blood cells and adipose tissue in humans. 
2.4.3.3 Biomarkers of Phthalate Exposure  
A reliable biomarker is needed to quantify phthalate exposure in specific human body 
fluids.  There have been different recommendations regarding the ideal biomarker.  Very few 
studies have been conducted to quantify diester phthalates in human serum (45, 48, 49, 54).  
Quantification of diester phthalates is limited to study with special population undergoing 
medical interventions (e.g., dialysis, ventilation, intravenous resuscitation) (15, 17).  In many 
human studies, phthalate metabolites, monoesters and/or oxidized metabolites have been 
quantified in biological fluids to estimate exposure (18, 46, 47, 182, 199).  Urinary monoester 
metabolites of some commonly used phthalates, such as DEP, DBP and BBP have been 
recommended as good indicators of phthalate exposure in humans (40). Concentrations of 
thirteen hydrolyzed and oxidized phthalate metabolites were quantified in the serum, urine and 
seminal plasma of Danish men (47).  In this study, it was proposed that serum MEP and mono- 
isobutyl phthalate (MiBP) could be used as biomarkers of exposure because of the correlation 
between urinary and serum concentrations of MEP and MiBP.  Urinary excretions of metabolites 
in order of highest to lowest concentrations were: MEHP, MEP, MiBP, MnBP and MBzP.  
Several metabolites were detected in much lesser concentrations in serum compared to urine; 
only MEP in seminal plasma correlated with that in urine and blood (47).   
Pregnancy is a unique situation during which the fetus may be exposed to phthalates.  
The amniotic fluid undergoes complete turnover every 3 hours; therefore, there is continuous 
exposure to the fetus via the amniotic fluid (46).  During pregnancy and lactation, the assessment 
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of maternal urine metabolites may not accurately extrapolate to fetal and neonatal exposure and 
phthalate transmission into amniotic fluid and breast milk, respectively (45, 46).  Phthalate 
metabolites in maternal serum are more likely to represent fetal exposure via placental blood 
transfer.  
Research to determine whether phthalates concentrations in body fluids and tissues are 
associated with adverse health risks is complex.  The most appropriate body fluid and tissue and 
the best analytical compound that will reflect exposure must be found.  Quantification of 
oxidized metabolites and monoesters in both urine and serum has been recommended to improve 
the evaluation of exposure to phthalates (15, 199).  Kato et al., conducted a study in 127 human 
participants to assess the exposure to DEHP using MEHP and two oxidized metabolites 
(MEOHP and MEHHP) as biomarkers in both urine and blood serum (199).  The concentrations 
of oxidized metabolites excreted in urine, primarily in the glucuronidated form, were 10 times 
higher compared to the levels of MEHP.  Oxidized metabolites were detected in <50% serum 
samples (mainly in the conjugated form) at a lower concentration than that in urine.  As 
phthalates have short half-lives, concentrations will vary from time-to-time depending on daily 
activities.   
Sampling technique and storage have been evaluated as confounders in quantifying 
concentrations.  The frequency of sampling of urine has been taken into consideration in some 
studies (15, 200).  Although a single urine sample at a single point in time was moderately 
predictive of exposure of a subject over 3 months, sampling urine on multiple occasions was 
recommended to determine exposures over weeks or months (15, 200).  Day-to-day and month-
to-month variability in urinary phthalate concentrations were reported over a 3 month-period 
(200).  However, in another study, urine phthalate metabolite concentrations did not differ 
between two consecutive sampling days (201).  Metabolite concentrations in the fresh vs. stored 
urine samples were not different (202). 
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2.4.4 Potential Adverse Effects of EDCs on Reproduction 
2.4.4.1 Animal Studies 
2.4.4.1.1 Phthalates and Animal Reproduction 
 Many animal studies have been conducted over the past 50 years to clarify the effects of 
phthalates on the body systems.  Research in animals, predominantly on rats, has provided 
evidence that phthalates have the potential to interfere with reproduction and development (23, 
203-205).  DEHP and its metabolite MEHP have been shown to exert ovarian toxicity in cycling 
female rats (27, 28, 206).  Toxicodynamic effects mediated by MEHP included: lengthening 
estrous cycles, inhibiting ovulation, and reducing preovulatory follicle diameter by inhibiting 
granulosa cell proliferation and decreasing circulatory estradiol.  Disruption of estradiol 
biosynthesis resulted in increased serum FSH and inhibition of LH surge.  Absence of the LH 
surge prevented ovulation and thus lowered progesterone levels.  Other phthalate metabolites, 
such as MEP, mono-butyl phthalate (MBP) and mono-methyl phthalate (MMP) were not 
reported to exert any adverse effects on female reproduction.  However, effects have been 
reported with DBP and BBzP; implantation failure has been observed in the exposed pregnant 
and pseudo-pregnant rats (20, 21) 
  Mechanisms to explain how phthalates interrupt estradiol biosynthesis have been under 
investigation.  In rodents, it has been proposed that MEHP interferes with steroidogenesis in 2 
ways: 1) by suppressing FSH-stimulated cAMP production (207, 208); and 2) by indirectly 
activating the intra-nuclear PPARs and decreasing aromatase transcription in granulosa cells 
(208).  PPARs act as transcription factors and regulate gene expression.  The activation of  intra-
nuclear PPARs results  in a number of molecular consequences including decreased aromatase 
messenger ribonucleic acid (mRNA) expression, increased 17β-hydroxysteroid dehydrogenase 
(17β-HSD-IV) transcription, and increased fatty acid binding protein (FABP) synthesis (208).  
FABP transports MEHP inside cells. Phthalates have been also implicated as a mechanism to 
alter hormonal regulation of the HPG axis.  In a study in ewes, DEHP was found to alter the LH 
pulse frequency by disrupting the HPG axis instead of exerting a direct toxic effect on the ovary 
(209).  
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Phthalates have been found to cause testicular toxicity in animals.  Peroxisome 
proliferation and subsequent alterations in cholesterol and fatty acid metabolism have been 
established as mechanisms of DEHP induced liver toxicity.  However, a similar role for DEHP in 
eliciting testicular and developmental toxicity has not been found (210).  Rather, alterations of 
gonocytes and reductions in Sertoli cells have been implicated in testicular toxicity in neonatal 
rats (211, 212).  Even a comparatively low dose of MEHP disrupted Sertoli cell–gonocyte 
physical interactions and suppressed Sertoli cell proliferation (212).  Sertoli cell number was 
reduced in rats exposed to DEHP during neonatal and adult life (213).  MEHP caused early 
collapse of Sertoli cell vimentin filaments, which was suggested to induce germ cell apoptosis 
(214).  However, fertility status was undisturbed in adults who had been exposed to phthalates in 
prenatal life (215).  
Testicular Leydig cells may also be a target of phthalate toxicity following perinatal 
exposure.  It has been documented that decreased testosterone synthesis by the Leydig cells leads 
to “androgen deprivation syndrome” or “testicular dysgenesis syndrome (TDS)”.  This syndrome 
includes developmental abnormalities of the epididymis, seminal vesicles and prostate as well as 
hypospadias, cryptorchidism, persistent nipples, lowered sperm count and reduced AGD (22-24, 
204, 205, 216-218).  
The mode of action of phthalates on fetal testicular Leydig cells has been widely studied 
in animals.  Oral exposure to DEHP, BBP, or DBP during critical periods of intra-uterine life 
(gestation days 12-21) have been shown to elicit adverse effects in rats (22).  Hydrolyzed 
monoesters readily cross the rat placenta and reach the fetus (219, 220).  DBP was shown to 
interrupt the testosterone biosynthetic pathway by down regulating most of the genes for 
enzymes involved in Leydig cell androgen biosynthesis and signaling.  The important enzymes 
for testosterone biosynthesis that were targeted were: scavenger receptor class B-1, SRB1 
(receptor for the high-density lipoprotein); steroidogenic acute regulator protein (StAR); P450 
side-chain cleavage enzyme, P450scc (enzyme involved in the conversion of cholesterol to 
pregnenolone); 3beta-hydroxysteroid dehydrogenase, 3β-HSD (enzyme involved in the 
conversion of pregnenolone to progesterone); CYP17 (enzyme involved in the conversion 
progesterone to androstenedione; and c-kit (receptor for the stem-cell factor) genes in rats (22, 
221).  Alterations in cholesterol transport genes and impairment of cholesterol transport and 
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metabolism have been suggested as a plausible mechanisms of testosterone biosynthesis 
disruption in DBP exposed rats (221).  DEHP exposed fetal rats expressed inactivation of 
insulin-like factor 3 (insI3) gene, which may have been related to altered gubernaculum 
development, undescended testis and cryptorchidism (222).  Other developmental abnormalities 
reported following DEHP exposure in pregnant rodents included reduced implantation rate, 
increased fetal resorption, and decreased fetal body weight (223).  Additional mechanisms of 
endocrine disruption for phthalates have been proposed.  A recent study has investigated the 
“critical mechanism of toxicity” (CMTA) of four main types of phthalates (DHEP, DEP, DBP 
and BBP) at different concentrations in developing fish embryos.  Oxidative stress has been 
suggested as the CMTA for DEHP and DEP (11).   
2.4.4.1.2 BPA and Animal Reproduction 
Research has been conducted in animals over the past 15 years to determine associations 
between BPA and reproductive dysfunction.  Bisphenol A has been implicated in the induction 
of various physiological and pathological changes in the female reproductive system.  Examples 
include inhibition of folliculogenesis and ovulation, recurrent miscarriage, the development of 
ovarian cysts, oviductal lesions, endometrial hyperplasia, uterine polyps, cervical sarcoma, 
mammary adenocarcinoma, changes in brain structure and chemistry, and changes in adult 
behavior (27, 28, 206).  In animal studies, prenatal exposure to BPA at environmentally relevant 
doses adversely affected embryonic development of the female reproductive tract and 
reproductive function in adult life (5, 30, 224-226).  BPA has been also been shown to interfere 
with multiple stages of oogenesis in the developing ovary.  In BPA exposed female fetal rats, 
abnormal meiosis, interference with the encapsulation of oocytes into follicles, and disruption of 
maturation of oocytes in the adult ovary were reported (227-230).   
In addition to direct effects on follicles and oocytes, BPA has been shown to affect 
steroidogenesis.  It has been suggested that BPA exerts its effects by interfering with estrogen 
hormone-receptor interactions (31).  BPA can act as both an agonist and a competitive 
inhibitor/antagonist of endogenous estrogen receptors in rats.  BPA binds to nuclear estrogen 
receptors with a lower affinity (i.e., 10,000 -100,000 fold weaker) than 17-beta estradiol (E2).  
However, the affinity of BPA for G-protein coupled transmembrane estrogen receptors is 
unknown (7, 231).  It is plausible that BPA may stimulate altered cellular function, abnormal cell 
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proliferation and organ development, and endocrine disruption even at extremely low levels via 
the indirect G-protein pathway.  Like an endocrine hormone, a non-linear dose response 
relationship exists between BPA concentration and the number of bound receptors and the 
maximal observable biological effects (232).  BPA does not need to be present at high levels to 
have an effect upon the endocrine system (233).  Exposure to BPA has been also proven to alter 
the expression of homeobox genes (HOX-10 & 11) and may lead to reproductive tract 
malformation in female neonatal mice (4, 234).  BPA has also been reported to interfere with 
epigenetic mechanisms (i.e., hypomethylation of cytosine-guanine dinucleotide in DNA) leading 
to alterations in developmental programming in mice (235-238).  BPA has found to cause down 
regulation of vaginal estrogen receptors in the prenatally exposed female offspring leading to an 
altered vaginal morphology in the post-pubertal mice (225).  Furthermore, fetal BPA exposure at 
a dose higher than the lowest-observed-adverse-effect level (LOAEL) in Sprague-Dawley rats 
led to dysregulation of the HPG axis and caused anovulation, development of ovarian cysts and 
infertility (146).  
Effects of xenoestrogens, such as BPA or diethylstilbestrol (DES) have been explored 
during embryogenesis in male mice.  Exposure to a low dose of BPA or DES triggered a long 
AGD, an increase in prostate size and a decrease in epididymal weight (239).  It has been 
suggested that prostate enlargement occurs because of enhanced androgen receptor binding.  In 
contrast, a high dose of DES triggered a decrease in prostate weight, short AGD, and small 
fibrotic descended or undescended testes and sterility; decreasing androgen receptor binding was 
thought to be the cause (239, 240).  Adverse effects on pregnancy included an increase in post-
implantation pregnancy loss and a decrease in litter size.  Low sperm count and hormonal 
imbalances have been reported in adult rats exposed to BPA prenatally (241).   
Direct effects of BPA on pubertal and adult reproductive function have been investigated.  
BPA may disrupt male fertility by altering the testicular expression of Sertoli cell junctional 
protein (SCJP) in developing testes (241).  Treatment of mice with BPA during puberty resulted 
in a significant drop of free testosterone and the development of multinucleated giant cells in 
seminiferous tubules of the testis (242).  However, no gross alterations in spermatogenesis have 
been reported in adult rats following in-utero exposure to BPA (243).  Bisphenol A can act as an 
antagonist of DHT (32-34).  Modulation of multiple steps of the activation and function of 
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androgen receptors (AR) has been observed.  Bisphenol A inhibited androgen receptor binding 
directly or altered the interaction of the androgen receptor with its co-activator (ASC1) (33).  In 
addition, BPA has been found to modify androgen-induced transcriptional activity and androgen 
receptor nuclear translocation (33).    
2.4.4.2 Human Studies 
2.4.4.2.1 Phthalates and Human Reproduction 
Scientific findings obtained to date on the potential adverse effects of phthalates on 
human reproductive health have been inconclusive.  Of the limited studies conducted, few focus 
on the female reproductive system.  Most studies lacked sensitivity and selectivity, and have 
been limited by considerable background contamination.   
The relationships between phthalate metabolites and reproductive dysfunction in men 
have been investigated.  Different parameters of male fertility, such as semen quality and 
concentrations of steroid hormones have been examined.  Urine MBP and MBzP levels have 
been associated with poor semen parameters and decreased serum testosterone, FSH, and LH in 
men (2, 15, 244-246).  In 269 men, correlations between urinary phthalate metabolites and 
abnormal semen parameters were reported (247).  The findings included positive associations 
between urinary concentrations of MEHHP, MEHP and mono-iso nonyl phthalate (MiNP) and 
decreased sperm motility; MBP and abnormal CASA parameters, such as straight-line velocity 
(VSL), curvilinear velocity (VCL), and linearity (LIN); MEHP and decreased testosterone, FSH 
and LH production; MBP and an increased sperm DNA damage; and MBzP, MBP, MEHP and 
MEP and sperm aneuploidy.  In another study, comparisons between CASA parameters and 
different urinary phthalate metabolites, such as MEP, MBzP, MBP, MEHP and mono-methyl 
phthalate (MMP) were examined (248).  No associations between urinary MEP, MBzP or MEHP 
concentrations and CASA parameters were detected.  In contrast,  MBP positively correlated 
with abnormal sperm motility and low sperm concentration; MBzP with abnormal sperm 
motility; and MEP with high sperm DNA damage (244).  Duty et al. also investigated 
correlations between urine phthalate metabolites and serum reproductive hormone levels (249).  
The inverse relationships between MBzP and FSH, and MEHP and testosterone were found; 
however, there was a positive correlation between MBP and inhibin-B.  The link between 13 
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urinary phthalate metabolites and serum testosterone levels was explored in different age groups 
from the national health and nutrition examination survey (NHANES).  An inverse relation was 
found only between DEHP metabolites and serum testosterone among men 40-60 years of age 
(38).  More recently, anti-androgenic effects of DEHP metabolites have been documented (250).  
The negative correlations between serum DEHP metabolites and serum testosterone, sex 
hormone-binding globulin, semen volume, and total sperm count have been reported (250). 
Associations between phthalates and female reproductive dysfunctions have been also 
reported in only a few human studies.  Women with endometriosis had significantly greater 
plasma DEHP concentrations compared to the control group, and 92.6% had detectable DEHP 
and /or MEHP in the peritoneal fluid (49).  The study groups identified a need to further evaluate 
toxicokinetics of phthalate metabolites as a means to bio-monitor and assess risks due to 
phthalate exposure.  High concentrations of serum phthalate (e.g., DEP, DBP, DMP, and DEHP 
and its major metabolite MEHP) were observed in the majority of Puerto Rican girls with 
premature thelarche (54).  In a separate study, however, no relationship was found between 
pubertal maturation and neonatal DEHP exposure (251).   
Phthalate concentrations have been compared between fertile and infertile couples.  
Concentrations of five hydrolyzed metabolites (MEHP, MEHHP, MEP, MBP, MBzP) in spot 
urine samples were compared between 56 infertile Italian couples undergoing assisted 
reproduction techniques for the diagnosis of endometriosis, tubal factors, ovulatory disorders, 
unexplained and male factor infertility, and 56 fertile couples (18).  There were greater urinary 
excretion of phthalate metabolites in infertile couples compared to fertile couples; however, no 
differences were detected between men and women (18).   
Phthalates have been quantified in amniotic fluid and breast milk to assess fetal and 
neonatal exposure.  A positive linear correlation between maternal urine and fetal amniotic fluid 
concentrations of phthalate metabolites has been shown (46).  Oxidative metabolites of 
phthalates were detected in amniotic fluid for the first time in this study; however, concentrations 
were much lower compared to the maternal urinary levels.  These findings provided rationale for 
further research to assess fetal metabolism and adverse fetal health effect of phthalates.  No 
correlation between metabolites in urine and breast milk was found (46).  
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2.4.4.2.2 Bisphenol A and Human Reproduction 
Evidence demonstrating negative influences of BPA on human reproduction has been 
seen. Adverse effects of BPA during IVF treatment have been shown to include poor ovarian 
response to stimulation drugs, a reduction of the number and quality of mature oocytes and 
fertilized oocytes, and decreased fertilization rates (252, 253).  Lowered peak serum estradiol 
levels following gonadotropin stimulation (254); abnormal semen parameters such as low sperm 
count, abnormal morphology, decreased motility, and increased sperm DNA damage (37); poor 
embryo quality (255); and implantation failure (256) have been further associated with BPA 
exposure in infertility patients. Concentrations of BPA were positively correlated with serum 
total/free testosterone concentrations in women with PCOS (257).  Similarly, serum BPA was 
greater in women with PCOS (both with and without obesity) compared to a control group (258).  
Women with PCOS also had higher serum dehydroepiandrosterone sulfate (DHEAS) and 
androgens compared the non-PCOS women (258).  However, it is not yet clear whether BPA is a 
cause or consequence of PCOS.  High serum BPA might also be related to insulin resistance in 
women with PCOS (259).  Women with endometriosis exhibited greater serum and urine BPA 
concentrations when compared to women without endometriosis (39, 260).  Inverse relationships 
between urinary BPA concentrations and free androgen index (FAI, a ratio of testosterone to sex 
hormone binding globulin), estradiol, estradiol:testosterone ratio, thyroid stimulating hormone 
and inhibin-B were reported.  On the contrary, positive associations between serum FSH and the 
FSH:inhibin ratio have been found in the men undergoing infertility treatment (261).  No 
correlation was found between unexplained infertility and urinary BPA in Chinese men 
undergoing assisted reproduction (262).  Patients with complex endometrial hyperplasia and 
cancer showed lower serum BPA levels compared to those with simple endometrial hyperplasia 
(263).  Exposure to BPA has also been positively associated with obesity (264-266).   
Exposure to BPA in the workplace has been investigated.  Male participants working in 
epoxy resin plants who had high urinary BPA levels exhibited sexual dysfunction and poor 
sperm quality (267-270).  BPA has also been found to alter reproductive hormone concentration 
in many studies.  BPA exposed workers had greater urinary BPA and lower FSH than the 
unexposed control populations (271).  High urinary BPA was associated with high serum SHBG 
in both men and women (272, 273).  Exposure to BPA (via urine) has also been associated with a 
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low serum free androgen index and FAI:LH ratio in men (273).  However, in a separate study, 
urinary BPA concentration and serum testosterone were not correlated (272).  High serum 
prolactin levels have been reported in women exposed to BPA in their workplace (274).   
There have been contradictory findings about Bisphenol A and adverse pregnancy 
outcomes.  In some studies, it has been suggested that serum BPA in women is positively 
associated with recurrent miscarriages (275, 276), low birth weight (277) and premature delivery 
(in a pilot study) (278).  However, in another study, no relationship between BPA and birth 
weight was detected (279, 280).  Prenatal occupational exposure to BPA was positively 
correlated with a low neonatal birth weight and a short anogenital distance in infant boys (281).  
In contrast, concentrations of BPA in umbilical cord blood were not greater in cryptorchid 
newborn boys compared with the unaffected boys (controls) (282).  Similarly, BPA and 
phthalate metabolites in maternal urine were not found to be greater in newborn boys with 
cryptorchism and hypospadiasis compared to those without the anomalies (283).   
2.5 Methods for Quantifying Exposure to Serum Phthalates 
2.5.1 Liquid Chromatography coupled with Mass Spectrometry (LC-MS/MS)  
Liquid chromatography and mass spectrometry (LC-MS/MS) is often used to measure a 
wide range of compounds, such as pharmaceuticals, environmental contaminants, foods and 
industrial materials.  Liquid chromatography separates compounds based on the differential 
partitioning between the mobile and stationary phases (283).  In LC, the liquid phase is a liquid 
and the stationary phase is a column.  Columns are of different sizes, and contain various 
retardant chemicals to separate compounds based on their physiochemical properties.  The 
column is either normal or reversed phase.  In a normal phase column, hydrophilic chemicals 
(such as silica, aluminum resins and spherisorbs) are used to retard the hydrophilic compounds.  
In contrast, in reversed phase columns, hydrophobic chemicals (such as alkyl-phenyl, C18) 
enhance the separation of lipophilic compounds including phthalates.  Compounds are detected 
according to their properties by use of ultraviolet light, fluorescence or electric conductivity 
(283).  LC analytical methods qualify and quantify a compound based on the unique retention 
time and peak absorption in the electromagnetic wave length, respectively (283, 284).  LC 
provides a good resolution chromatogram for a single compound; however, it cannot accurately 
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quantify multiple unknown compounds eluted at the same retention time.  Thus, coupling of LC 
with mass spectrometry (MS) provides a powerful technique for accurately separating and 
detecting a range of compounds (286). 
Liquid chromatography coupled with MS has become a method of choice for phthalate 
detection due to its high sensitivity, selectivity and reproducibility.  After separation of 
compounds using LC, MS detects analytes based on the mass to charge ratio (m/z) (284).  The 
MS system measures gas phase ions while the LC measures ions in the liquid phase.  It is 
therefore necessary to vaporize the liquid and to apply a charge to the analyte in order for it to be 
analyzed.  The most common ionization methods include chemical ionization (CI), electrospray 
ionization (ESI), atmospheric pressure chemical ionization (APCI) and atmospheric pressure 
photoionization (APPI) (287).  Each method ionizes and vaporizes samples differently.  For 
example, APCI applies a charge at a corona discharge needle while APPI uses ultraviolet light to 
apply a charge (287).  Thus, the method used determines which compounds will be detected and 
the limits of detection.  Charged ions are then passed through the mass analyzers of MS (286).    
In mass spectrometry, different types of mass analyzers (such as quadruple, magnetic 
sector, time of flight (TOF), electrostatic sector and ion cyclotron resonance) are used for 
separation and identification of ions (286).  Quadrupole and magnetic sector mass analyzers use 
an electric or magnetic field to separate ions, respectively.  By comparison, TOF separates ions 
by time needed to pass the tube depending on the kinetic energy and velocity of the ions.  A 
single quadrupole MS is only able to separate precursor molecules based on their m/z.  However, 
in the triple quadrupole MS, the first quadrupole receives the precursor/parent molecule.  The 
second quadrupole stabilizes the ion and impacts it with an inert gas causing each precursor ion 
to fragment, a condition which is called collision induced disassociation (CID).  The third 
quadrupole detects the fragment/daughter ions based on the m/z ratio (286, 287).  Use of triple 
quadrupole enhances the reliability of compound identification by identifying both precursor and 
fragment ions.  The quantity of specific ions that hit the detector is then converted to a signal.  
This signal is manipulated by software to display different peaks for specific ions.  
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Figure 2.5.1:  The triple quadrupoles of mass spectrometry (MS/MS).  Specific functions of the 
triple quadrupoles are illustrated.  The quadrupole Q1 detects precursor ions 
based on m/z; the quadrupole Q2 causes fragmentation of precursor ions by 
collision induced dissociation (CID); and the quadrupole Q3 detects product ions 
based on m/z.  The m/z refers to mass to charge ratio. 
 
2.5.2 Phthalate detection by use of Liquid versus Gas Chromatography coupled with MS  
In addition to LC-MS, gas chromatography and mass spectrometry (GC-MS) has been 
used to quantify phthalate concentrations in biologic samples.  There are some advantages of 
LC-MS over GC-MS.  There is a wide range of acceptability of compounds that can be analyzed, 
including stable chemicals in a liquid or gaseous form, thermally unstable chemicals and least 
volatile compounds.  There is less sample processing, no derivatization required, superior 
detection limit, and a shorter analysis time.  There is a higher degree of confidence due to the 
presence of the quasi molecular ion and characteristic fragment ion (288).  However, matrix 
interferences and background contamination from solvents and tubing are the two major 
problems associated with the use of LC-MS.  By comparison, application of GC-MS is limited to 
only gases or volatile substances with high thermal stability.  The GC-MS has lower limits of 
detection, and requires greater sample processing that in turn leads to greater contamination risk 
compared to LC-MS (288).  Most analytical methods for phthalates from food matrices have 
utilized GC-MS (289).  However, due to increasing reliability and sensitivity, LC-MS/MS 
methods are being developed.  This method is often employed to study exposure, distribution and 
metabolic excretion of phthalates in various biological matrices (47, 290).  Phthalates and 
metabolites have been detected in human urine, serum, breast milk, saliva, ovarian follicular 
fluid, seminal plasma and amniotic fluid samples by use of LC-MS/MS (41, 43, 290-295). 
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2.5.3 Phthalate extraction 
Samples are purified and concentrated prior to phthalate quantification by LCMS.  Both 
solid phase (SPE) and liquid/liquid (LLE) extraction methods have been employed and validated 
to extract phthalates.  Extraction methods are applicable to cell cultures and plasma samples - 
fresh, frozen or archived.  Phthalates have been extracted from milk and milk products (i.e., 
infant formula) using liquid/liquid extraction with a mixture of methyl tert-butyl ether (BME) 
and hexane (289).  Milk fats were removed from DBP, BBP and DEHP by use of acetonitrile, 
while DINP and DIDP were isolated with use of deactivated silica.  DEHP and MEHP have been 
simultaneously detected in seminal plasma by liquid-liquid extraction followed by isocratic 
reversed-phase chromatography with diode-array detection (295).  Munch et al., used both LLE 
and SPE followed by GC-MS during the detection of phthalate esters in drinking water (296).  In 
many human studies, phthalates metabolites were measured in biological matrices using 
automated SPE followed by LC-MS analysis (18, 44, 45, 48, 292, 293, 297).  Silva et al., 
quantified eleven phthalate metabolites in human urine using automated SPE (293).  Both liquid 
and automated SPE were used before GC-MS analysis (45).  The automated SPE method 
involved two extractions with hexane/methyl tert-butyl ether (1:1) and then one extraction with 
hexane, followed by separation on an amino propylene column.  Enzymatic degradation of 
diester phthalates before extraction is a potential drawback as it can falsely depress 
concentrations of the parent compound in samples. 
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Hydrolytic enzymes present in biological fluids can hydrolyze diester phthalates.  The 
hydrolysis of environmental diesters leads to falsely elevated concentration of monoesters in 
samples.  In order to measure the enzymatic hydrolysis in samples, phthalate spiked serum 
samples were incubated at 370C with or without adding phosphoric acid (47, 199).  Addition of 
phosphoric acid caused acid denaturation of the hydrolytic enzymes to eliminate potential 
enzymatic degradation of diester phthalates.  Denaturation of enzymes by acid prevented false 
elevations or depressions of monoester and diester phthalates, respectively.  In many studies, 
analytic methods have also incorporated enzymatic deconjugation of phthalate metabolites with 
β-glucuronidase (18, 45, 182).  In order to measure conjugated metabolites, E. Coli K-12 β-
glucuronidase enzyme and ammonium acetate buffer were added to samples and were incubated 
at 37 °C for 90 min (182, 293).  However, no enzyme deconjugation was needed to measure free 
metabolites. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
47 
CHAPTER 3: RATIONALE 
An increase in reproductive dysfunction, including infertility, has been observed in men 
and women over the past two decades. The current prevalence of infertility ranges from 11.5% to 
15.7% in Canada (55), compared to a range of 3.5 to 26.4 % worldwide (298-300).  More 
specifically, unexplained infertility is a common diagnosis among infertile couples, with a 
prevalence of 15%-30% (301).  It has been postulated that phthalates are causally related to 
infertility in humans.  This postulate is based on studies conducted primarily in animals (5, 22, 
23, 203, 205, 208, 222).  Few studies have been conducted to evaluate an association between 
EDC concentrations and human fertility.  No studies have been conducted to quantify phthalates 
in men and women in Saskatchewan.  Data from a proof of principle study in our lab revealed 
that there may be greater serum BPA concentration in male and/or female partners of couples 
diagnosed with unexplained infertility compared to fertile controls.  We also found that phthalate 
concentrations in the cellular component of blood was greater in women with PCOS compared to 
controls (302), Baerwald et al., unpublished data).  Further investigations are needed to confirm 
our preliminary data.   
In this study, blood, follicular fluid, and seminal plasma samples were collected from 
infertile couples undergoing IVF treatment.  In addition, blood samples were collected from 
healthy fertile men and women with proven fertility.  The original objective of our research was 
to quantify and compare concentrations of both phthalates and BPA in fertile versus infertile men 
and women.  Due to unforeseen logistical limitations with study recruitment, equipment 
malfunctions, and attainment of research funding, we were only able to evaluate phthalate 
concentrations.  Follicular fluid samples were evaluated.  However, phthalate concentrations 
were undetectable using large sample aliquots.  Seminal plasma samples have been collected but 
have not been analyzed.   
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CHAPTER 4: GENERAL OBJECTIVES 
The main objective of the study contained in this thesis was: 
 
To determine whether serum phthalate concentrations differ in men and women with 
infertility compared to those without infertility in Saskatchewan. 
 
 
 
CHAPTER 5: GENERAL HYPOTHESES 
The hypotheses were that: 
 
1. Serum phthalate concentrations would be greater in infertile versus fertile men. 
 
2. Serum phthalate concentrations would be greater in infertile versus fertile women. 
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CHAPTER 6 
Comparative Serum Phthalate Concentrations between Fertile versus Infertile 
 Men and Women in Saskatchewan 
Roy S1, Baerwald A1, Chizen D1, Mankidy R2, Coldling G2, Case A3, Gamelin A3, McVee J3, 
and  Giesy J 2 
1Department of Obstetrics, Gynecology & Reproductive Sciences, College of Medicine        
University of Saskatchewan, Saskatoon, Saskatchewan; 
2Toxicology Center, University of Saskatchewan, Saskatoon, Saskatchewan; 
3AURORA Reproductive Care Center, Saskatoon, Saskatchewan 
 
6.1 Abstract  
Objective: To determine whether serum phthalate concentrations differ in men and women with 
infertility compared to those without infertility in Saskatchewan  
Hypothesis: Serum phthalate concentrations will be greater in men and women with infertility 
compared to fertile men and women 
Setting: Patients undergoing assisted reproduction for the treatment of infertility; healthy 
volunteers recruited from the community 
Recruitment and sample collection: Infertile couples were recruited prior to in vitro 
fertilization (IVF) therapy for treatment of unexplained infertility (n=15), polycystic ovarian 
syndrome (PCOS, n=13), and male factor infertility (n=12).  Fertile men (n=15) and women 
(n=15) were recruited using poster advertisements.  Blood samples were collected by 
venipuncture for phthalate analysis. 
Main outcome measures: Serum phthalates concentrations (ng/mL)  
Design: Prospective cohort pilot study 
Methods: In infertile couples, blood samples were collected on the following 3 days of the IVF 
cycle: early during ovarian stimulation, day of oocyte retrieval and day of embryo transfer.  In 
healthy volunteers, 3 blood samples were collected over a 2 week period. Liquid 
chromatography and tandem mass spectrometry (LC-MS/MS) was conducted to quantify 
concentrations of four phthalates: di-n-butyl phthalate (DBP), diethyl phthalate (DEP), di-(2-
ethylhexyl) phthalate (DEHP) and diisodecyl phthalate (DIDP).  Phthalate concentrations were 
compared among the four study groups using non-parametric Kruskal-Wallis and Mann-Whitney 
U post hoc tests. 
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Results: Serum DEHP and DEP concentrations did not differ among control, unexplained, 
PCOS, and male factor infertility groups in both men and women (p>0.05).  DBP in women did 
not differ among study groups (p=0.205).  In contrast, DBP was lesser in men with unexplained, 
PCOS, and male factor infertility compared to controls (p < 0.05).  Similarly, DIDP was lesser in 
women of couples with unexplained, PCOS and male factor infertility groups compared to fertile 
women (p < 0.05).  Less DIDP was detected in men with unexplained and male factor infertility 
compared to the control group (p < 0.05) 
Conclusion: Serum phthalate concentrations in serum were lesser or not different in infertility 
patients undergoing IVF compared to fertile volunteers.  These findings do not support the 
notion that serum phthalate concentrations are associated with human infertility.  Further 
research is needed to determine whether phthalate concentration in blood cells and adipose tissue 
differ in infertile versus fertile men and women. 
Key words: Phthalates, PCOS, Unexplained infertility, Male factor infertility  
 
 
Ms. Sandhya Roy participated in all aspects of conducting this study. She was involved in study design (20%) , 
participant recruitment (70 %), sample collection (90%), sample processing and LCMS analyses (90%), as well as 
data acquisition, statistical analyses and knowledge translation (90%).  
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6.2 Introduction 
The human endocrine system is highly complex.  The main functions of the endocrine 
system are to synthesize and release hormones which regulate the growth, development, and 
metabolism of organs and body systems.  In addition to endogenous endocrine hormones, many 
chemicals in the environment can affect bodily processes.  EDCs are hormonally active 
heterogeneous groups of exogenous agents.  EDCs can mimic or interfere with the action of 
endogenous endocrine hormones including reproductive, thyroid, adrenal and pituitary hormones 
(1).  Research conducted in animals, and to a lesser extent in humans, over the past 50 years has 
provided evidence that EDCs may cause a wide range of diseases and disabilities including 
obesity, diabetes, cancer, heart disease, thyroid disease, reproductive dysfunction, 
neurodevelopmental and neurodegenerative disorders (2).  The most obvious effects of EDC are 
adverse effects on reproductive function and early fetal development (3-5). 
Animal models have been used to investigate the biological effects of EDCs.  Many 
animal studies have been conducted to understand the molecular mechanisms of action of EDCs, 
with a particular focus on toxicodynamic effects at low-dose exposures typical of environmental 
exposure (232, 233, 303).  The EDCs may exert its effect(s) by a number of mechanisms 
including: 1) acting as an estrogen or aryl hydrocarbon receptor agonist, 2) acting as estrogen or 
androgen antagonist, 3) altering steroidogenic enzymes gene expression, 4) disrupting 
gonadotropin hormone production, 5) indirect interfering with steroidogenesis by alteration of 
cell membrane ion exchange, 6) inducing epigenetic changes, and/or 7) inducing oxidative stress 
(6-11).  Direct effects on gametes (i.e., oocytes, sperm) have also been reported (12). 
Hundreds of EDCs, either natural or man-made, are present in the environment.  More 
than 500 chemicals are known or suspected to have endocrine disrupting potential (13, 14).  
Phthalates are a group of synthetic EDCs which are of particular concern because of their 
omnipresence, widespread use and high production (5).  Women, men and children are 
continuously exposed to these chemicals through contaminants in the air, water, soil, dust, 
children’s products, personal-care products (e.g., perfumes, lotions and cosmetics), construction 
materials, paint, medical devices and pharmaceuticals.  Phthalates are a family of industrial 
compounds with a common chemical structure, dialkyl or alkyl/aryl esters of 1, 2-
benzenedicarboxylic acid.  Phthalates are primarily used to increase the flexibility, transparency, 
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durability and longevity of plastics (15, 16).  As phthalates are not chemically bound to 
polymers, chemicals easily leach from their plastic matrix, become volatilized, move into the 
environment and ultimately enter into the food chain (15, 16).  Worldwide, more than 8.2 
million tons of phthalates are used every year.  DEHP is the most commonly used, at 2 
million tons of use per year (15-19).  
Several adverse biological effects have been attributed to phthalates.  Phthalates are not 
classified as carcinogens (International Agency for Research on Cancer).  Rather, phthalates 
have been found to cause teratogenicity, developmental anomalies, and reproductive toxicity in 
animals (20-23).  Phthalates, particularly DBP and DEHP have been studied to examine 
reproductive toxicity and developmental abnormalities in animals (23-26).  Anti-androgenic 
effects, such as short anogenital distance (AGD), cryptorchidism, decreased testosterone 
concentrations and decreased sperm production have been reported after exposure in-utero (23-
26).  It has been also found that DEHP and its bioactive metabolite, MEHP cause ovarian 
toxicity in cycling rats by prolonging the estrous cycle, inhibiting ovulation and decreasing 
systemic estradiol  (27, 28).   
Most of the studies have been completed primarily in animal models; further research is 
needed to elucidate the impact of phthalates in humans.  Metabolites of phthalates have been 
detected in human body fluids including urine, serum, breast milk, saliva, sweat, ovarian 
follicular fluid, seminal plasma, peritoneal fluid and amniotic fluid (3, 39-48).  However, limited 
data, methodological inconsistencies, and high background contamination in many studies have 
led to contradictory and debatable results about potential adverse reproductive effects.  
Intrauterine exposure to low dose environmental phthalates has been associated with short AGD 
and incomplete testicular descent in men (35), similar to studies in animals.  Inverse correlations 
between urinary phthalate metabolites, semen quality and reproductive hormones have been 
reported in men (15, 36-38).  Phthalates have been termed as obesogens (29) due to their 
association with obesity.  Low dose exposure, particularly during the fetal period, has been 
linked with childhood obesity (29).  Associations between phthalate exposure and reproductive 
dysfunction have been explored in some studies (18, 39, 49).  Greater phthalates and /or 
metabolites have been detected in women with endometriosis compared to the control group 
(49), and in infertile couples compared to fertile couples (18). 
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A decline in reproductive health has been observed in men and women within 
industrialized countries (51).  The reasons for this decline are generally unknown.  The 
worrisome decrease in fertility has been manifested as: reduced semen parameters, infertility and 
testicular cancer in men; various congenital abnormalities of the reproductive tract in both men 
and women; a decline in pregnancy and birthrate; and an early onset of puberty and menopause 
in women (50-53).  Currently the prevalence of infertility in Canada (11.5-15.7%) is similar to 
that of other industrialized countries (10-15%) (55, 56).  The underlying pathophysiology for 
many etiologies of infertility is not fully understood.  Infertility is diagnosed when a couple fails 
to conceive within 12 months of unprotected intercourse.  Unexplained infertility is diagnosed in 
15%-30% of infertile couples and is characterized by no identifiable cause for reproductive 
dysfunction.  Because of the associations reported between EDC exposure and reproductive 
dysfunction in animals, there has been concern that EDC may be causally related to human 
infertility.  There is paucity of research to investigate the relationship between EDCs, 
particularly phthalates, and different types of human infertility.  To date, no studies have been 
conducted to quantify BPA and phthalates concentration in men and women in Saskatchewan.  
Data from a pilot study in our lab have suggested that serum BPA concentration were greater in 
male and/or female partners of couples diagnosed with unexplained infertility compared to 
controls.  We further found that phthalate concentration in the cellular component of blood were 
greater in women with PCOS compared to controls (Baerwald et al., unpublished data).  Further 
research in a larger sample of men and women is needed to confirm these preliminary findings.   
6.3 Materials and Methods 
A prospective cohort pilot study was conducted in among the Department of Obstetrics, 
Gynecology and Reproductive Sciences at the University of Saskatchewan, the Toxicology 
Center at the University of Saskatchewan, and the Aurora Reproductive Care Center of 
Saskatoon.  The study was completed from 2012 to 2014.  Study procedures were conducted in 
accordance with the Tri-Council Policy Statement on the Ethical Conduct of Research Involving 
Humans.  The study protocol was approved by the Biomedical Research Ethics Committee at the 
University of Saskatchewan (U of S) and the Strategic Planning and Priorities Committee at the 
Saskatoon Health Region (Appendix A).  Informed consent was obtained from all participants 
prior to initiating study procedures (Appendix A). 
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6.3.1 Participant Recruitment: 
 Infertile couples undergoing assisted reproduction with the following diagnosis were 
recruited: unexplained infertility (n=15 male partners, n=15 female partners), PCOS (n=15 male 
partners, n=15 female partners) and male factor infertility (n=15 male partners, n=15 female 
partners), were designed to recruit.  Infertile patients were enrolled from the Aurora 
Reproductive Care Center in Saskatoon, Saskatchewan.  Both the male and female partners of 
infertile couples were required to participate.  Couples with a combination of both male and 
female factor infertility were excluded.   
 Healthy volunteers (n=15 men, n=15 women) were enrolled.  Inclusion criteria included 
proven fertility status and no history of reproductive dysfunction.  Healthy volunteers were 
recruited from the University community and Saskatoon Health Region through electronic and 
paper advertisements. 
6.3.2 Sample Collection and Preparation 
 Multiple blood samples were needed to determine the day to day variability of phthalate 
concentrations over time.  Three samples were collected over a 2 week period in both fertile and 
infertile groups.  Blood samples were collected from infertility patients on the following days 
during fertility treatment: (1) within the first 7 days of ovarian stimulation, (2) day of egg 
retrieval, and (3) day of embryo transfer.  These 3 days were chosen based on the practicality of 
obtaining blood, follicular fluid and seminal plasma samples.  Three blood samples were also 
collected from the healthy volunteers over a 2 week period.  It was not possible to collect 
follicular fluid and seminal plasma from the healthy women and men, respectively.   
 At each visit, approximately 7 mL of blood was collected into a glass tube (BD 
Vacutainer #366340, 367342; Franklin Lakes, NJ USA).  Blood samples were allowed to clot for 
30 minutes, and then centrifuged at 2000 rpm for 20 minutes.  The cellular and serum 
components of the blood samples were separated using glass pipettes and immediately frozen at -
20◦C in 15 mL polypropylene conical centrifuge tubes (Evergreen, Fisher Scientific, Cat#:08-
558-33C) until analysis.  Serum samples were transferred frozen to the Toxicology Center, and 
thawed at room temperature prior to extraction.  All sample collection and preparation 
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procedures were conducted according to the Standard Operating Procedures (Environmental 
Toxicology Lab, University of Saskatchewan) (304-306). 
6.3.3 Chemicals  
All chemicals used in this study were HPLC grade or greater (Fisher Scientific, Ottawa, 
Ontario).  As initial tests of solvents used for phthalate quantification indicated contamination, 
all chemicals were distilled prior to use and tested periodically.  
6.3.4 Extraction  
Thawed serum samples were mixed for 30 sec using a vortex shaker.  Serum samples (0.5 
mL) were transferred into 6 mL labeled glass culture tubes along with 10µl of deuterated internal 
standard, IS (500 ng/mL of D4-BBP) and 0.5 mL distilled methanol.  After adding methanol, 
samples were again vortexed for 30 sec.  Next, 2.5 mL of a 1:1 mixture of Hexane and MTBE 
was added to each tube.  Each sample was vortexed for 1 min, and centrifuged at 2000 RPM for 
2 minutes.  The supernatant from each sample was carefully collected into a culture tube without 
disturbing the water fraction, and the extraction steps were repeated using Hexane and MTBE.  
The combined extract was evaporated under a gentle stream of nitrogen (N2).  Samples were 
reconstituted with 4 mL 50/50 hexane acetonitrile (ACN) and vortex-mixed for 1 min.  The top 
hexane layer was discarded and the bottom ACN fraction was collected and taken to dryness 
under steady nitrogen gas.  Samples were reconstituted in 100 µL ACN and transferred to a gas 
chromatography vial (289, 307). 
6.3.5 Instrumental Analysis   
Phthalates in serum were quantified by LC-MS/MS using a HPLC (Agilent 1200 series 
Santa Clara, CA-95051) coupled to a PE Sciex triple quadruple mass spectrometer (API-3000 
Framingham, USA).  Separation of target analytes was performed using a Phenyl column (ACE 
Phenyl, 50 x 2.1mm, 3um Canadian Life Science Peterborough ON), with a sample run time of 
18 mins.  Solvents consisted of nanopure water with 0.1% acetic acid (solvent A), and distilled 
methanol with 0.1% acetic acid (solvent B).  Initial operating conditions were 40% solvent A 
holding for 1 min changing to 100% solvent B over 2.5 min, and remaining at 100% solvent B 
for 13.5 minutes.  A switch was made to 60% solvent B at 16 mins for the remaining 2 mins.  A 
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guard column placed after the solvent pump was used to mitigate contamination from carrier 
solvents.  The Mass Spectrometer, operating in positive mode ESI, used multiple reactions 
monitoring (MRM).  Each phthalate compound was quantified using precursor and/or two 
product/daughter ions (Figure 6.3.1 and 6.3.2, Appendix B).  The full list of compounds 
quantified is shown in Table 6.3.1.  Mass spectrometer operating conditions were as follows: ion 
spray voltage=3500 volts, capillary temperature=350°C and gas flow rates=12, 8 and 12 AU for 
nebulizer, curtain and collision gases respectively.  Concentrations were derived from a 12 point 
calibration curve of target analytes with a range from 1ng/mL to 0.01mg/mL.  Concentrations > 
0.01mg/mL caused depression of the internal standard, and did not distinguish the target peak 
from interference peaks generated from contamination.  Samples were integrated using Analyst 
4.1 software (Agilent Technologies). 
 
Table 6.3.1: List of quantifying analytes including precursor and/or two quantifying 
fragment/daughter ions 
 
 
 
 
Compound Abbreviation Molar Mass Precursor Ions Quantifying Ions (s) 
Diethyl phthalate DEP 222.24 223 149 121 
di-2-ethylhexyl phthalate DEHP 390.56 391 149 167 
Benzylbutyl phthalate BBP 312.36 313 149 205 
Diisodecyl phthalate DIDP 446.66 447 149 205 
Di-n-butyl phthalate DBP 278.34 279 149 205 
D4- benzylbutyl phthalate 
(IS) 
D4-BBP 316.36 317 153  
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6.3.6 Quality Assurance and Quality Control (QA/QC) 
During all phases of this experiment, precautions were taken where possible to avoid 
phthalate contamination through the use of plastic materials.  However, many items in the lab 
were potential unavoidable sources of contamination.  Therefore, a wide range of blanks were 
generated to control these inputs.  A schematic representation of background contamination and 
methods to assess and control for contamination in the reproductive and toxicology lab is shown 
in Figure 6.3.3. 
 
  
 
 
 
 
 
Figure 6.3.3: Potential sources of background contamination of phthalates and methods to 
assess and control for contamination from the reproductive and toxicology lab.  
On multiple occasions, nanopure water was exposed to all the glassware, plastics 
and chemicals that were used during sample collection, cryopreservation, 
extraction and analyses procedures to obtain an average background 
contamination for each phthalate. 
 
For each set of 20 samples, there was a set of quality control samples that included a 
solvent blank, duplicate matrix blank (fetal bovine plasma for blood serum samples), and method 
blank (nanopure water).  All samples were spiked with a 10 µL surrogate deuterated IS (D4-BBP 
500 ng/mL).  The percent recovery of the IS (i.e., ratio of IS value in each sample versus average 
IS value in standards X 100) ranged from 12-50% with a median value of 29%.  Matrix spikes 
were used to determine the accuracy of the extraction from blood serum and to monitor sample 
Blanks for blood collection using 
nanopure water  
3 blanks with each extraction batch  
Methanol and acid-methanol injections 
after each 6-12 samples during LC-MS 
Reproductive Lab Sources Toxicology Lab Sources 
Nitrile plastic gloves, plastic capped 
vaccutainer needles, plastic cryotubes and 
air 
Nitrile plastic gloves, plastic 
pipette tips, solvents and air 
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matrix effects that could interfere with the analytes of interest.  Surrogate spike samples were 
needed to monitor the quantitative transfer of the phthalate compounds throughout the sample 
extraction to LC-MS/MS detection phases.  Method blanks included either a solvent or matrix 
blank.  Blank samples included labware where nanopure water rather than plasma was added.  
Blanks were extracted along with the samples to monitor any contamination that might be 
introduced from sample collection, processing, storage and extraction. 
Quality checks on the LC-MS/MS consisted of methanol and 1% acetic acid methanol 
injections every 6 and 12 samples respectively plus standard injections after 12 samples to check 
for instrument drift.  Full 12 point calibration curves run prior to and after each batch of 40 
samples were obtained by plotting peak area vs. concentration.  Samples were integrated 
following a limit of detection (LOD) of 3 times the baseline.  Methanol injection values were 
subtracted from sample values to account for contamination by the final solvent (which ranged 
from 0.3 to 4.6% of the mean detection of target analytes).  Because initial sample runs indicated 
concentrations >0.01mg/mL for some analytes, samples were diluted 10 fold and reanalyzed to 
stay within the calibration curve.  Standard calibration curves for HPLC analysis were 
formulated by plotting peak area and concentration.  The equations for standard of DEHP, DEP, 
DBP and DIDP were obtained through regression analysis (Figure 6.3.4).  The methanol 
subtracted sample value was divided by the corresponding IS value to calculate the sample 
response value (ŷ).  Fixed concentrations (x) (ng/ml solvent/0.5 mL serum) for each phthalate 
were calculated by using value of ŷ, intercept (β0) and slope (β1) in the standard regression 
equation (ŷ= β1x+β0).  Final phthalate concentrations were obtained by dividing the x value by 
10 (for ng/100 µL solvent), and then multiplying by 2 (for 1 mL serum) and 10 (for the dilution 
factor).  Blood serum data were reported as ng/mL.  The final phthalate concentrations in blanks 
and samples were evaluated to calculate the method detection limit (MDL) or LOD.  
The nanopure water was exposed on multiple occasions to all the glassware, plastics and 
chemicals that were used during sample collection, cryopreservation, extraction and analyses 
procedures in order to obtain background contaminations.  The average contamination for each 
phthalate of interest was calculated.  The MDL was arbitrarily set at average of the background 
concentrations (3-fold value of the solvent blanks).  Any sample value below this MDL was 
considered non-detectable.  Phthalate concentrations which were above the MDL were 
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considered for further statistical analyses.  We originally planned to quantify concentrations of 
five phthalates: DEHP, DEP, DBP, DiDP, and BBP.  BBP was excluded from our analyses due 
to its detection below the MDL.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3.4:  Standard curves showing the regression lines with regression equations and R2 
(regression coefficient) for DEHP, DEP, DBP and DIDP.  Phthalates 
concentrations in samples were calculated by using the standard regression 
equations for each phthalate. 
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6.3.7 Statistical Analysis 
Average concentrations of DEHP, DEP, DBP and DIDP over the 3 study visits were 
compared among the study groups using non-parametric Kruskal-Wallis and Mann-Whitney U 
post hoc tests (SPSS version 22).  Only samples with values which were above the MDL were 
included in our analyses. Alpha was set at 0.05 for all statistical analyses. 
6.4 Results  
Average background contaminations from sample collection to toxicologic analysis 
procedures for different phthalates were quantified.  The range of background phthalate 
concentration was approximately 500-26,000 ng/mL.  The greatest contamination level was 
found for DBP and the least for DEP (Table 6.4.1).   
Table 6.4.1: Mean background concentrations (ng/mL) of 4 phthalates with ranges intruded 
from the clinical and toxicologic analysis procedures. 
 
 
 
 
 
 
Serum concentrations of DEHP were compared among control, unexplained, PCOS, and 
male factor infertility groups in men and women.  No difference in serum DEHP concentrations 
were found among the 4 study groups for both men and women (Figure 6.4.1). 
 
 
 
 
Phthalates Background concentrations (ng/mL) 
  
DEHP 14,811 (11,026-17,713) 
DEP 583 (513-689) 
DBP 23,223 (21,216-26,228) 
DIDP 13,720 (13,375-14,077) 
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Figure 6.4.1:  Comparisons of serum DEHP concentration among fertile versus infertile men 
and women.  Data are shown as median + interquartile range. The x-axis 
represents the 4 study groups and y-axis represents serum DEHP concentrations 
(ng/mL).  Sample size in each group (data above MDL) is indicated by n. 
 
 
P=0.425 
P=0.418 
n=13 n=5 n=6 
n=13 n=12 n=8 n=6 
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Serum concentrations of DEP were compared among control, unexplained, PCOS, and 
male factor infertility in men and women.  No differences in DEP concentrations were found 
among the 4 study groups for both men and women (Figure 6.4.2) 
 
 
 
 
 
 
 
 
 
 
Figure 6.4.2:  Comparisons of serum DEP concentration among fertile versus infertile men and 
women.  Data are shown as median + interquartile range.  The x-axis represents 
the 4 study groups and the y-axis represents serum DEP concentrations (ng/mL).  
Sample size in each group (data above MDL) is indicated by n. 
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Serum concentrations of DBP in men and women were compared between control, 
unexplained, PCOS and male factor infertility groups.  Serum DBP in women did not differ 
between the control, unexplained, PCOS and male factor infertility groups (p=0.205).  However, 
mean serum DBP was less in men of couples with unexplained, PCOS and male factor infertility 
compared to the control group (p < 0.05) (Figure 6.4.3).   
 
 
Figure 6.4.3: Comparisons of serum DBP concentration among fertile versus infertile men and 
women.  Data are shown as median + interquartile range.  The x-axis represents 
the 4 study groups and the y-axis represents serum DBP concentrations (ng/mL). 
Sample size in each group (data above MDL) is indicated by n.  a,b Groups with 
different superscripts were different (p<0.05).   
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Serum concentrations of DIDP in men and women were compared between control, 
unexplained, PCOS and male factor infertility groups.  Serum DIDP in both women and men 
differed between the control, unexplained, PCOS, and male factor infertility (p=0.015 and 
p=0.0005).  Serum DIDP in women were greater in the control group compared to unexplained, 
PCOS and male factor infertility groups (p < 0.05).  Serum DIDP were greater in the control 
group compared to men of couples with unexplained and male factor infertility compared to 
controls (p < 0.05, Figure 6.4.4). 
 
 
Figure 6.4.4:  Comparisons of serum DIDP concentration among fertile versus infertile men 
and women.  Data are shown as median + interquartile range.  The x-axis 
represents the 4 study groups and the y-axis represents serum DIDP 
concentrations (ng/mL).  Sample size in each group (data above MDL) is 
indicated by n.  a,b,c Groups with different superscripts were different (p<0.05). 
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A second set of analyses were conducted to regroup study participants.  Specifically, 
male partners of women with PCOS and female partners of men with male factor infertility were 
included in the control groups. Serum DEHP was compared among control, unexplained and 
PCOS groups in women and control, unexplained and male factor infertility groups in men.  No 
difference in serum DEHP concentrations were found among the 3 study groups for either men 
or women (Figure 6.4.5). 
 
 
 
 
Figure 6.4.5:  Results of secondary analyses conducted using modified study groups. 
Comparisons of serum DEHP concentration among fertile versus infertile men 
and women are reported.  Data are shown as median + interquartile range.  The 
X-axis represents the 3 study groups and y-axis represents serum DEHP 
concentrations (ng/mL).  Sample size in each group is indicated as n. 
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Serum DEP was compared among control, unexplained and PCOS groups in women and 
control, unexplained and male factor infertility groups in men.  No differences in serum DEP 
concentrations were found among the 3 study groups for either men or women (Figure 6.4.6). 
 
 
 
 
 
Figure 6.4.6:  Results of secondary analyses conducted using modified study groups.  
Comparisons of serum DEP concentration among fertile versus infertile men and 
women are reported.  Data are shown as median + interquartile range.  The X-
axis represents the 3 study groups and y-axis represents serum DEP 
concentrations (ng/mL).  Sample size in each group is indicated as n. 
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Serum DBP was compared among control, unexplained and PCOS groups in women and 
control, unexplained and male factor infertility groups in men.  No difference in serum DBP 
concentrations were found among the 3 study groups for either men or women (Figure 6.4.7). 
 
  
  
 
 
 
 
Figure 6.4.7:  Results of secondary analyses conducted using modified study groups.  
Comparisons of serum DBP concentration among fertile versus infertile men and 
women are reported.  Data are shown as median + interquartile range.  The X-
axis represents the 3 study groups and y-axis represents serum DBP 
concentrations (ng/mL).  Sample size in each group is indicated as n. 
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Serum DIDP were compared among control, unexplained and PCOS groups in women 
and control, unexplained and male factor infertility groups in men.  No difference in serum DIDP 
concentrations were found among the 3 study groups for women.  Serum DIDP was greater in 
the control group compared to unexplained and male factor infertility groups (p < 0.05) (Figure 
6.4.8). 
 
  
 
  
Figure 6.4.8:  Results of secondary analyses conducted using modified study groups.  
Comparisons of serum DIDP concentration among fertile versus infertile men 
and women are reported.  Data are shown as median + interquartile range.  The 
X-axis represents the 3 study groups and y-axis represents serum DIDP 
concentrations (ng/mL).  Sample size in each group is indicated as n.   a,b Groups 
with different superscripts were different (p<0.05). 
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Serum concentrations of DEHP, DBP and DIDP were compared among the 3 study visits.  
No differences in serum DEHP, DBP and DIDP concentrations were observed among the 3 study 
visits for any of the study groups (Figure 6.4.9 a-f). 
 
 
 
 
 
a 
b p >0.05 
p >0.05 
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Figure 6.4.9:  Comparisons of serum phthalate concentrations among the 3 visits in the 4 
diagnostic groups (a-f).  Data are shown as median + standard error. 
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6.5 Discussion 
In this pilot study, we quantified phthalate concentrations in human serum.  After 
developing methods for quantification of phthalates (Giesy et al., unpublished data), phthalate 
diester concentrations were compared among infertile and fertile men and women in 
Saskatchewan.  Serum concentrations of DEHP and DEP were not different in infertile versus 
fertile men and women.  On the contrary, in men, DBP was greater in the control group 
compared to infertility patients.  Similarly, DIDP in both men and women were greater in the 
control group compared to infertility patients.  Thus, our hypotheses were not supported.   
Few studies have been conducted to elucidate potential adverse effects of phthalates on 
human fertility.  Findings from our study do not support preliminary data previously obtained by 
our group and others.  Since initiating our study, greater urinary phthalate metabolites have been 
reported in infertile versus fertile couples (18).  In addition, serum DEHP levels have been found 
to be greater in women with versus without endometriosis (49).  Inconsistencies among the 
present and previous studies may be attributed to differences in analytic compounds (metabolites 
vs. diesters) evaluated and body fluids (urine vs. serum) analyzed as well as variations in the 
sensitivity of analytical methods used. 
In most human studies, phthalate metabolites have been quantified in urine samples.  
Very few studies have been conducted, to our knowledge, to quantify diester phthalates in human 
serum (45, 48, 49, 54).  This is the first study in which human serum diester phthalates have been 
quantified in men and women of Saskatchewan.  In the present study, the approximate median 
serum phthalate concentrations (ng/ml) in the fertile men and women were: DEHP: 29,000 and 
26,500; DBP: 89,500 and 75,000; and DIDP: 16,500 and 15,500.  Local Saskatchewan phthalate 
concentrations were remarkably greater (i.e., approximately 1000X) than those reported 
previously in Swedish postpartum (45).  In comparison, median serum DEHP concentrations 
(µg/ml) in Italian women with endometriosis were reported to be approximately 100 times lower 
than those of infertility patients in our study (56).  Similarly, median serum DEHP 
concentrations were 10 times lower in a previous study conducted in Puerto Rican pubertal girls 
(49) compared to the present study.  Participant socio-demographic profiles, lifestyle factors 
(e.g., fresh vs. preserved foods), health status (e.g., healthy vs. hospitalized), pathophysiological 
conditions (e.g., endometriosis, premature thelarche), differences in methods used (LC-MS vs. 
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GC-MS) as well as assay sensitivity may in part, contribute to inconsistent findings among 
studies. 
Several factors may have contributed to similar or lesser phthalate concentrations in 
infertility patients compared to fertile volunteers.  First, in the process of obtaining consent, 
infertility patients were informed about emerging scientific evidence regarding EDCs and 
potential adverse reproductive effects.  Knowing the financial and psychosocial burden of 
infertility treatment, couples may have subconsciously or consciously reduced phthalate 
exposures from all possible sources through lifestyle changes in order to optimize their chances 
of conceiving (although they were instructed not to do so).  Second, BMI may be a potential 
confounder to our study findings.  Since initiating our study, associations between BMI, lifestyle 
factors and phthalate exposure have been documented (308, 309).  Third, infertile men and 
women may exhibit differential phthalate toxicokinetics (e.g., absorption, distribution, 
metabolism and excretion).  It is possible that infertility patients may be genetically predisposed 
to metabolize phthalates more quickly, leading to lower concentrations compared to controls.  
Also, serum may not be the best endpoint to evaluate diester phthalates.  The lipophilic nature of 
diester phthalates may result in sequestration in blood cells and fat, thereby leading to lower 
concentrations in serum.  The notion of phthalate sequestration in tissues is supported by the 
finding that DEHP concentration in sweat exceeded levels found in urine or serum (48).  In some 
human studies, environmental contaminants (i.e., p,p'-DDE, PCBs, BPA and heavy metals 
(cadmium, lead, mercury) were found to accumulate in follicular fluid in infertile women (310, 
311).   Phthalate concentrations in follicular fluid were evaluated in our study; however, no 
diester phthalates could be detected.  Lastly, diesters may not be the best biomarker of phthalate 
exposure.  The ubiquitous nature of phthalate diesters leads to ongoing challenges to reduce 
background contamination.  It has been recently suggested that phthalate monoesters and/or their 
oxidized urinary metabolites may be a better biomarker than serum diester phthalates.  Urinary 
oxidized metabolites were detected at greater concentrations (around 10 fold) and with lesser 
background contamination compared to the monoesters in urine (2, 15, 17, 47, 182). 
Phthalates have short half-lives.  Therefore, one may expect blood concentrations to vary 
from time-to-time, depending on daily activities.  In this study, no differences in serum phthalate 
measurements were observed over the 2 week study period.  We interpret these findings to mean 
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that phthalate exposures and thus serum levels do not vary substantially from day-to-day, due to 
their ubiquitous presence.   
The biggest limitation of this study was the small sample size.  With that said, the 
findings of this pilot study provide rationale for continued investigations to increase our 
understanding of potential effects of phthalates on the human reproduction.  Another limitation 
to the study of phthalates in any lab is unavoidable background contamination.  We made a 
conscious effort to minimize contamination by using phthalate-free labware and plastics with 
low levels of phthalates, whenever possible.  With that said, potential sources of parent diester 
phthalate contamination included plastic blood storage tubes, plastic gloves, plastic pipette tips, 
solvents and air.  Both LC-MS and GC-MS methods have been used for phthalate quantification.  
Both methods are continuously evolving and present both advantages and disadvantages.  Since 
initiating our study, solid phase extraction followed by GC-MS has been proposed as an optimal 
method for measuring phthalate exposure, due to less background noise.  However, this method 
is often cost-prohibitive, and involves more extensive sample processing. 
6.6 Summary 
In this pilot study, serum phthalate concentrations of DEHP, DEP, DBP and DIDP were 
either not different or less in men and women undergoing assisted reproduction compared to 
fertile controls.  These findings are a first step in quantifying serum concentrations of phthalates 
in men and women of Saskatchewan.  Our findings indicate widespread environmental phthalate 
exposures in both fertile and infertile populations, but at present, do not support the notion that 
phthalates have adverse effects on human fertility.  Results of the present study provide rationale 
for continued research to quantify lipophilic diester phthalates in adipose tissue and blood cells, 
with additional consideration of BMI and lifestyle factors. 
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CHAPTER 7: GENERAL DISCUSSION 
A prospective, observational pilot study was conducted among the Department of 
Obstetrics, Gynecology and Reproductive Science and the Toxicology Center at the University 
of Saskatchewan as well as AURORA Reproductive Care Center in Saskatoon, Saskatchewan.  
The objective of this collaborative project was to test the hypothesis that serum phthalate 
concentrations would be greater in infertile versus fertile men and women in Saskatchewan.  Our 
hypothesis was based on data from a previous proof of principle study in which we reported the 
following: DEHP concentrations in the cellular component of blood were greater in women with 
PCOS compared to controls; and BPA concentrations in blood serum were greater in men and 
women with unexplained infertility compared to controls.  In the present study, we found that 
phthalate concentrations were not greater in infertile patients compared to healthy fertile 
volunteers.  Thus, the hypotheses in the present study were not supported.   
There is a paucity of research to elucidate potential associations between human 
reproductive function and quantification of phthalate exposure.  Information about phthalate 
concentrations in the environment and inside the human body is helpful to minimize potential 
health risks that may result from exposure.  Investigations must be conducted in different 
geographic regions in order to determine region-specific potential adverse effects. This is the 
first study in which serum phthalate concentrations were evaluated in men and women in 
Saskatchewan.  Median phthalate concentrations (ng/mL) in control groups were as follows: 1) 
DEHP: 28,703 in men and 26,534 in women, 2) DBP: 89,322 in men and 74,529 in women, 3) 
DIDP: 16,350 in men and 15,707 in women.  The phthalate levels in our study were 
approximately 1000X greater those reported previously in Swedish postpartum women (45).  
Högberg et al. reported that the serum concentration of phthalates were ranged 0.31 to 5.9 ng/mL 
and their metabolites 0.77 to 1.8 ng/mL.  However, the sensitivity of the assays in the Högberg’s 
study was questioned providing a possible explanation for differences between studies.  
Similarly, median serum DEHP concentrations (µg/ml) were 10 times greater in the present 
study compared to a previous study in Puerto Rican girls between 6 months to 8 years of age 
with premature thelarche (56).  The reported serum diester phthalate concentrations in the Peurto 
Rican girls were:  DEHP (0.18- 2.0 µg/ml), DBP (0.01-0.27 µg/ml) and DEP (0.008-0.02 µg/ml).  
By comparison, serum phthalate concentrations in our study were: DEHP (26-28 µg/ml), DBP 
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(74-89 µg/ml) and DEP (0.6-5.8 µg/ml).  Participant socio-demographic profiles, 
pathophysiological conditions, difference in methods used, lifestyle factors, health status, and 
sensitivity of analytical techniques may contribute to the discrepancies in phthalate 
concentrations between the studies. 
Proportional contributions of phthalates from various environmental sources in different 
age groups have been reported in the following descending order: air (43–50%) > drinking water 
(24–34%) > foodstuffs (19–24.5%) > dust (3–5.5%) > soil (<0.2%).  Moreover, the daily intake 
(ng/kg-body weight/day) of phthalates has been quantified in the following descending order: 
DBP (277–368) > DEHP (149–203) > DMP (97–131) > DEP (25–37) > BBP (1.8–2.5) > DOP 
(1.5–2.1) (184).  After controlling for background contamination, we detected serum diester 
concentrations (µg/ml) in a similar pattern in the control groups: DBP (51-135), DEHP (15- 49) 
and DEP (0.6-5.8).  DBP and then DEHP exceeded that of other phthalates in serum. 
In a prior study, greater urinary metabolites have been reported in infertile versus fertile 
couples (18).  Tranfo et al. (2012) studied Italian infertile couples undergoing treatment for 
endometriosis, unexplained infertility, tubal diseases, anovulation, and male infertility.  Urinary 
metabolites (MEP, MEHP, MEHHP, MBzP and MnBP) were found to be greater in infertile 
versus fertile couples.  By comparison, in our study we found that serum phthalates were either 
similar or greater in control groups compared to infertile groups.  Although almost similar study 
groups and analytical methods were used between the 2 study, inconsistencies of findings may 
be attributed to differences in analytic compounds used (metabolites vs. diesters) and body fluids 
evaluated (urine vs. serum).   
The unexpected findings of similar or lesser phthalate concentrations in infertility 
patients compared to fertile controls may be due to several factors.  First, infertility patients were 
informed about emerging scientific evidence regarding EDCs and potential adverse reproductive 
health during the consenting process.  Knowing the financial and psychosocial burden of 
infertility treatment, the couples may have subconsciously or consciously reduced phthalate 
exposures from all possible sources through lifestyle changes in order to optimize their chances 
of conceiving.  Second, BMI may have confounded our study findings.  Since initiating our 
study, associations between BMI and phthalate levels have been documented (308, 309).  In one 
study, both external (daily intake) and internal exposure (metabolites in urine) to phthalates were 
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quantified in obese participants undergoing weight reduction compared to non-obese participants 
(308).  No differences in urinary metabolite concentrations were observed between groups.  
However, urinary metabolites were elevated in obese participants that had lost weight over a 3 to 
6 month period.  In a separate study, positive correlations were detected between urinary 
phthalate metabolites and BMI as well as waist circumference (WC) in Chinese children (309).  
BMI data were not available for evaluation in the present study.  Future studies in our laboratory 
and others should include BMI as a potential confounder for associations (or lack thereof) 
between phthalates and human fertility. 
Third, infertile men and women may exhibit differential phthalate toxicokinetics 
compared to fertile controls.  That is, absorption, distribution, metabolism, and excretion of 
phthalates may differ in infertile versus fertile people.  For example, fertile couples might be 
genetically predisposed to metabolize phthalates more quickly, leading to lower concentrations 
compared to controls.  In addition, blood serum may not be the best biological tissue sample to 
quantify diester phthalates.  The lipophilic nature of diester phthalates may result in phthalates 
being sequestered in blood cells and fat, leading to lower concentrations in serum.  The notion of 
phthalate sequestration in tissues is supported by the finding that DEHP concentrations in sweat 
exceeded that found in urine or serum (48).  Lastly, serum phthalate diesters may not be the best 
endpoint to quantify internal phthalate exposures due to the ubiquitous nature of diesters.  There 
is an ongoing challenge with high background contamination of research samples with 
ubiquitous environmental diesters. 
Identifying an ideal biomarker for phthalate exposure in an appropriate body matrix has 
been a daunting task.  In some studies, monoester phthalate metabolites in urine and or serum 
have been used as a biomarker of exposure (40, 47, 291).  However, phthalate monoesters give a 
falsely elevated interpretation of exposure due to the contamination and breakdown of ubiquitous 
diester phthalates to their respective monoesters; this phenomenon of phthalate metabolism has 
been documented in many biological matrices, including urine, blood, seminal plasma, follicular 
fluid, amniotic fluid, peritoneal fluid and breast milk.  Furthermore, formation of oxidative 
metabolites occurs following enzymatic breakdown within the body, rather than by hydrolytic 
conversion of background environmental diester phthalates.  It has been suggested recently that 
oxidized metabolites in urine or serum may be a better biomarker to document exposure 
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compared to parent diester or monoester phthalates.  Urinary oxidized phthalate metabolites have 
been detected at a greater concentration (around 10 fold) and with lesser background 
contamination, and were thus presumed to avoid falsely elevated exposure levels (15, 17, 47, 
182).  It is important to recognize that urinary metabolite concentrations may vary according to a 
participant’s water intake and should be normalized by the urine creatinine value (18).  
Moreover, urinary maternal phthalates metabolites may not be the best predictor of fetal and 
newborn exposures via amniotic fluid and breast milk, respectively (45, 46).  Determining the 
ideal biomarker(s) in appropriate body fluid or tissue to quantify internal phthalate distribution 
has been controversial and provides rationale for further research to elucidate phthalate 
quantification in adipose tissue versus blood cells and/or serum. 
In some human studies, environmental contaminants (i.e., p,p'-DDE, PCBs, BPA, and 
heavy metals (cadmium, lead, mercury) were found to accumulate in FF in infertile women (310, 
311).  The results of these studies are contradictory (43, 312).  In 5 women undergoing oocyte 
retrieval, phthalates and their metabolites were detected in FF at a concentration below15 ng/ml.  
This phthalate concentration in FF was much lower compared to that reported in animal ovarian 
studies (43).  Similarly, BPA was not detected in labware used during the egg retrieval 
procedures in IVF (312).  Collectively, these findings suggest that BPA and phthalates neither 
preferentially accumulated in FF nor leached out from the labware and media used in IVF 
treatment (43, 312).  The main focus of the thesis work was to evaluate serum phthalate 
concentrations.  However, blood cells, follicular fluid and seminal plasma samples were also 
collected.  During our initial method development trial, we were not able to detect phthalates in a 
large volume of follicular fluid (i.e., up to 2 mL).  Continued investigations are required to 
quantify phthalates in human blood cells, seminal plasma and adipose tissue. 
Phthalates have a large octanol-water partition coefficient (i.e., Log Kow of DEHP = 7.5) 
which represents their high fat solubility.  It is generally thought that due to rapid and efficient 
metabolism, phthalates do not accumulate in the body.  However, findings of some studies have 
indicated the accumulation of phthalates in human tissues (48, 313, 314, 315).  Phthalates have 
been classified as one of the lipophilic persistent organic pollutants (POPs) family which are 
resistant to biotransformation and excretion from the body (313).  Other compounds belonging to 
this family are organochlorine pesticides, polychlorinated biphenyls (PCBs), dioxins, and 
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polybrominated flame retardants (BFRs) (313).  POPs accumulate in white adipose tissue and 
cause potential disruption of nuclear transcription factors necessary for differentiation, 
metabolism and secretory functions of fat cells (313).  Mes et al. (1974) quantified human 
postmortem DEHP and DBP concentrations at a range of 0.3-1 mg/ml and 0.1-0.3 mg/dl in 
adipose tissue.  DBP and DEHP could also be detected in the fatty component of human kidney 
autopsies.  These findings suggest a negative effect of phthalates on adipose tissue physiology 
and a potential relationship with pathological conditions such as diabetes, kidney disease, and 
PCOS.   In some animal studies, evidence of phthalate tissue bioaccumulation has been provided 
(315, 316, 317).  A significant proportion of phthalates from repeated small intravenous 
infusions was found to be retained for several months in the liver of rhesus monkeys (316).  
Similarly, in rats, the radioactivity of oral deuterated DEHP was reduced to only 1/3rd of the 
steady-state level in fat within 3 weeks (317).  
Phthalates are ubiquitous and have short half-lives.  As a result, it has been suggested that 
variations in serum concentrations may occur within a given day and across days.  Quantifying 
phthalates in body fluids over weeks or months rather than at a single point in time has been 
recommended, due to the transient changes that may occur in phthalate concentrations following 
daily activities (15, 200).  A single urine sample predicts phthalate exposure over 3 months; 
however, the predictabiliy varies among phthalate monoesters.  For example, predicability is 
high for MEP but low for MEHP (200).  In this study, three blood samples were collected to 
determine variations in concentrations over time.  Serum concentrations did not differ among the 
3 study visits over the 2 week period for any of the phthalates in any of the study groups.  The 
lack of variability in serum phthalate levels observed over time supported previous research 
findings in which urine phthalate metabolite concentrations did not differ between two sampling 
days (201).  Collectively, we interpreted these findings to mean that serum phthalate 
concentrations do not vary substantially from day-to-day due to their ubiquitous presence in the 
environment.  However, in another study,  day-to-day and month-to-month variability in 
phthalate metabolite concentrations in urine was found (200).  The day-to-day variance of urine 
metabolites ranged from 27.2% (MBP) to 58.5% (MMP), and the cycle–to-cycle variance ranged 
from 1.5% (MBP) to 16.3% (MEP).  Metabolite concentrations in the fresh vs. stored urine 
samples were compared and were not different (202).  However, blood sampling frequency and 
effect of prolonged storage on blood parent phthalates and/or metabolites have not been studied.  
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Further research is warranted to evaluate fresh versus stored blood samples collected on multiple 
occasions over months to account for variability in exposure. 
Due to the widespread presence of phthalates in the environment, background 
contamination from labware and equipment (e.g., solvents, reagents, glassware, air and others) is 
a fundamental problem when developing detection methods.  With this in mind, special attention 
was made to reduce contamination in the present study.  Whenever possible, approved glassware 
and specific plastics (e.g., use of nitrile plastic gloves, glass collection tube, vaccutainer needles 
versus collection sets with plastic tubing) were used to decrease contamination of samples.  
Blanks were run for several stages of study procedures to quantify background contamination.  
Blanks were run using nanopure water for sample collection, spinning, separation, 
cryopreservation, transportation, extraction and LC-MS analysis procedures.  In addition, all 
chemicals used in this study were HPLC grade or better.  All chemicals were distilled prior to 
use, and tested periodically.  After minimizing all preventable sources, additional potential 
sources of parent diester phthalate contamination included plastic blood storage tubes, plastic 
gloves, plastic pipette tips, and solvents, as well as air in the labs.  In future studies, minimizing 
background contamination through the use of dedicated and isolated laboratories with phthalate-
free air and equipment would be ideal.   
In the present study, male and female partners for each male or female infertility 
diagnostic group were evaluated separately.  For example, female partners of couples with male 
factor infertility were considered as a separate female study group, rather than considering them 
as controls.  Similarly, male partners of couples with PCOS were considered as a separate male 
study group rather than including them in the control group.  This approach was used in order to 
prevent sampling bias.  Because all couples were infertile, we could not be certain that the male 
partner of couples with PCOS or the female partner of couples with male factor infertility were 
truly fertile.  In an effort to increase our sample size, we conducted a second set of analyses to 
expand our control groups.  The male partners of women with PCOS and the female partners of 
men with male factor infertility were included in the control groups.  After regrouping, the study 
groups were reduced to three instead of four: control, unexplained and PCOS infertility for 
women; and control, unexplained and male factor infertility for men.  Secondary analyses of the 
modified study groups revealed that serum DIDP in men was greater in the control group 
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compared to unexplained and male factor groups.  No other differences were observed.  Thus, 
some of the differences in serum phthalates concentrations detected in our initial analyses were 
eliminated.  When we considered the initial and secondary analyses collectively, we further 
concluded that serum phthalates were either not different or lesser in the infertile groups 
compared to the healthy fertile volunteers. 
Limitations and future directions:  
The results of our pilot study have been an important first step for developing methods to 
elucidate potential associations between serum phthalate levels and adverse reproductive health 
outcomes in Saskatchewan.  The biggest limitation of this study was the small sample size.  A 
sample size of n=15 per group was considered adequate for a pilot project, considering our proof 
of principle findings.  Initially, the objectives of this research were to determine whether blood 
(serum and cells), follicular fluid and seminal plasma concentrations of BPA and phthalates 
differed in men and women with infertility compared to those without infertility.  Due to the time 
constraints, limited funding, and unforeseen logistical challenges with study recruitment, we 
were not able to quantify BPA concentrations in serum samples.  Furthermore, analyses of 
seminal plasma and blood cells have not been conducted. We anticipate continued evaluations of 
blood and seminal plasma samples collected.   
A second limitation of our research was that the background phthalate contamination 
(i.e., values below the MDL) limited the final sample size for evaluation.  As expected with 
relatively small datasets, exposure was not normally distributed.  Therefore, non-parametric 
statistical evaluations were performed.   
A third limitation of our study was that enzymatic degradation of diester phthalates by 
esterases in the serum may have led to falsely low quantification of diester phthalate.  Hence, the 
inability to pretreat samples with acid to denature esterase enzymes during or after collection 
may be considered as a pit-fall of this study.  With that said, freezing the samples shortly after 
they were obtained (within 60-90 min) would likely have minimized the enzymatic degradation 
of diester phthalates.  In future studies, effort should be given to fix the enzymatic breakdown of 
diester phthalates by adding acid immediately after collection. 
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 Additional research is required to optimize techniques to quantify phthalate 
concentrations using different body matrices.  Comparisons of diester versus metabolites 
(monoesters and oxidized metabolites) phthalate concentrations are required.  In order to 
improve methods, more specific knowledge about absorption, distribution, metabolism and 
excretion of phthalates through different routes of exposure is needed.  We are particularly 
interested in quantification of diester phthalates by analysis of fat biopsies and the role of BMI 
on phthalate levels in the body, and potential associated negative reproductive health effects.  
Age, dietary habits, caloric intake, level of activity, travel, smoking, and disease conditions may 
be additional potential confounders to consider.  The use of solid phase extraction (SPE) 
followed LC-MS or GC-MS should be considered when optimizing methods.  Minimizing 
background contamination through the use of dedicated and isolated laboratories with phthalate-
free air and equipment would be ideal. 
In summary, serum phthalate concentrations of DEHP, DEP, DBP and DIDP were either 
similar or greater in fertile men and women compared to infertile men and women undergoing 
assisted reproduction treatment.  Our findings do not support the notion that serum phthalates are 
associated with human infertility.  The findings from this pilot study suggest a ubiquitous nature 
of phthalate exposure in fertile and infertile men and women of Saskatchewan.  It is plausible 
that lifestyle factors and BMI may have confounded study findings.  As phthalates are lipophilic, 
they may have a tendency to be sequestered into tissues, particularly in fat cells.  Limitations 
aside, we believe that the results of our pilot study warrant continued investigations in a larger 
sample to document the potential effects of phthalates (in particular, in adipose tissue and blood 
cells) on human reproductive health. 
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CHAPTER 8: GENERAL CONCLUSION  
The results of the pilot study included in this thesis have suggested the following: 
1. Serum phthalate concentrations were not greater in infertile patients compared to healthy 
fertile volunteers:   
a) Median DBP concentrations were less in the male partners of couples with 
unexplained, PCOS, and male factor infertility compared to controls. 
b) Median DIDP concentrations were less in female partners of couples with 
unexplained, PCOS, and male factor infertility compared to controls. 
c) Median DIDP concentrations were less in male partners of couples with 
unexplained and male factor infertility compared to controls.   
 
2. Phthalate concentrations in men and women within the study groups did not differ over 
the time  
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Introduction: 
You (the woman) and your partner (the man) are being invited to participate in a research study. 
Please read the following information sheet and ask as many questions as necessary before you 
decide whether to participate. Please take time to read the following information carefully and to 
discuss it with your family, friends, and doctor before you decide. Your participation in this study is 
entirely voluntary, so it is up to you to decide whether or not to take part.  If you decide to take part 
in this study, you are both free to withdraw at any time without giving any reasons for your 
decision. If you choose to withdraw from this study, you will not lose the benefit of any medical 
care to which you are entitled or are presently receiving. 
 
Who is Conducting the Study? 
This study is being conducted by scientists and physicians in the Department of Obstetrics, 
Gynecology and Reproductive Sciences at the University of Saskatchewan and the Aurora 
Reproductive Care Center of Saskatoon. Funding to cover the administrative costs of conducting 
this study has been provided by the Royal University Hospital Foundation. The investigators are not 
being paid to conduct this study.  The investigators have no known or potential conflicts of interest 
in conducting this study.   
 
Why is this Study being Conducted? 
Research performed primarily in animals over the past 50 years has shown that pollutants in the 
environment may be causing damage to the reproductive tissues, cells, and gametes (i.e., eggs and 
sperm). ‘Endocrine Disrupting Chemicals’ (EDCs) are of particular interest because they interfere 
with the production and/or action of hormones that control reproductive processes. Bisphenol A 
(BPA) and phthalates are EDCs to which Canadians are continuously exposed through food and 
beverage containers, air, water, soil, construction materials, and children’s toys and products. BPA 
and phthalates have been detected in human serum, semen, amniotic fluid, follicular fluid (i.e., fluid 
in the sacs in the ovaries that contain the eggs), placental tissue, and breast milk; their metabolites 
have been measured in urine. However, the potential effects of exposure on human reproductive 
health are not fully understood. Furthermore, exposure to BPA and phthalates in people living in 
Saskatchewan has not been studied in detail.  
 
The overall objective of this study is to determine whether environmental exposure to BPA and/or 
phthalates negatively affects reproductive function in women and men. We will determine whether 
concentrations of BPA and/or phthalates differ in men and women with different types of infertility 
diagnoses compared to men and women without infertility. Greater knowledge about the possible 
effects of BPA and phthalates on reproductive function may increase our understanding of the 
causes of infertility, assist in preventing reproductive disease, and improve patient care.  We believe 
that the results of our study will be of interest to the general public and government agencies 
involved in regulating the manufacturing industry. 
 
What does the Study Involve? 
Couples undergoing IVF or ICSI for assisted reproduction as well as healthy male and female 
volunteers < 40 years of age will be asked to participate. In order for infertility patients to be 
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eligible, both the male and female partners must agree to participate. Couples undergoing 
infertility treatment for the following reasons will be evaluated: 
 
1. unexplained infertility (n=30 men, n=30 women) 
2. PCOS (n=30 men, n=30 women) 
3. Male factor infertility (n=30 men, n=30 women) 
 
Couples with a combination of both male and female factor infertility will not be eligible 
to participate. 
 
Additional participants will be assigned to the following control groups: 
 
4. Healthy volunteers with no history or current diagnosis of reproductive dysfunction 
 (n=30 men, n=30 women) 
 
Pre-Study Visit 
If you and your partner are eligible to participate in the study, you will be asked to visit Aurora 
Reproductive Care Center of Saskatoon for a pre-study appointment.  At this appointment, study 
procedures will be discussed with you and you may ask any questions about the study.  You and 
your partner will be asked to sign a consent form before initiating any study procedures.    
 
Study Visits 
If you agree to participate, you and your partner will undergo fertility treatment as per the normal 
standard of care. In other words, the fertility medications, ultrasound assessments, blood work 
during treatment, oocyte retrieval, semen collection, laboratory procedures and embryo transfer 
procedures that you undergo will not be affected by participating in this study. 
 
i. Blood Samples: 
You and your partner will be asked to provide 1 extra blood sample (approximately 7 mL or 1 
teaspoon of blood) on each of the following regularly-scheduled appointments: 
 
1. First ultrasound visit (approximately day 1 of FSH therapy) 
2. Day of egg retrieval 
3. Day of embryo transfer 
 
 
Women normally undergo regular blood draws during their IVF treatment; therefore, one 
additional tube will be drawn for research purposes at the regularly-scheduled blood draw 
appointments. Men do not normally provide a blood sample during IVF treatment, but will be 
asked to do so in this study. Blood draws will be performed by phlebotomists (staff that 
specialize in drawing blood) physicians, nurses.  
 
The blood samples will be processed to remove the cells, and the serum will be frozen for 6-9 
months until the completion of the study.   
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ii. Follicular Fluid Samples:  
The follicles in the woman’s ovaries will be drained and the eggs will be retrieved from the 
follicular fluid, as per the standard of care.  After the eggs are collected, the follicular fluid is 
normally thrown away.  In this study, we will collect the fluid from the follicles on each ovary 
after the eggs are retrieved. The follicular fluid will be frozen for 12-24 months until study 
completion. 
 
iii. Seminal Plasma Samples: 
A semen sample will be provided by the man on the day of the oocyte retrieval procedure, as per 
standard of care. The semen sample is processed by allowing the semen to pass through a 
column to separate the most motile sperm (moving very quickly) from the less motile and non-
motile sperm.  The seminal plasma is the fluid portion of the semen that remains after the most 
motile sperm have been obtained.  The seminal plasma is normally thrown away after the motile 
sperm are obtained.  In this study, we will collect the seminal plasma and freeze it for 12-24 
months until the study is completed. 
 
At the completion of the study all of the frozen blood, follicular fluid, and seminal plasma 
samples will be transported to the Toxicology Center at the University of Saskatchewan.  The 
levels of exposure to BPA and phthalates will be evaluated.  The samples will be destroyed upon 
completion of the study. 
 
You and your partner will have completed all study-related procedures once you undergo the 
embryo transfer procedures. The expected duration of study participation is approximately 13-20 
days. The only procedure that differs from the normal standard of care are the 3 extra blood 
samples that are collected from each of the male and female participants, as well as the use of 
follicular fluid and seminal plasma that are normally thrown away.   
 
What are the Possible Risks and Discomforts? 
Potential risks during study participation include: 
   -discomfort and bruising at the site of the blood draw 
 
What are the Benefits of Participating in this Study? 
There are no direct benefits for you or your partner to participate in this study. We believe that the 
results of this study may increase our understanding of the causes of male and female infertility and 
assist in the development of better treatment options for couples experiencing infertility.   
 
What Will the Study Cost Us? 
You will not be charged for participating in this study.  You will not be paid for participating in this 
study.  You will be responsible to pay for your fertility treatment.  
 
Will Our Participation be Kept Confidential? 
One of the objectives of our study is compare IVF outcomes in patients with different levels of 
exposure to BPA and phthalates.  Therefore, the results of your fertility treatment (eg. number and 
quality of follicles, oocytes and embryos that develop; fertilization rate, pregnancy rate) will be 
evaluated in this study.  In Saskatchewan, the Health Information Protection Act (HIPA) protects 
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the privacy of you and your partner’s personal health information. Your privacy will be 
respected. Your names will not be attached to any information, nor mentioned in any study report, 
nor be made available to anyone except the research team.  It is the intention of the research team to 
publish results of this research in scientific journals and to present the findings at related 
conferences and workshops, but your identities will not be revealed. 
 
What Happens if We Decide to Withdraw from the Study? 
Your participation in this study is voluntary. You and/or your partner may decide not to participate 
or withdraw at any time. You and/or your partner do not have to provide a reason to withdraw from 
the study.  If you choose not to participate in or withdraw from the study, it will not affect your 
future medical care. 
 
Please notify the study personnel as soon as possible if either of you wish to withdraw from the 
study.  If you voluntarily withdraw from the study and you do not want your data to be used in the 
study, your samples will be destroyed. 
 
Who Do We Contact if We Have Questions About the Study? 
If you or your partner have any questions regarding your participation in this study, please feel free 
to contact the Study Nurses (Jackie McVee, April Henry) at 306-653-5222 ext 239, Sandhya Roy 
(Research Co-ordinator) at 306-966-7851, Dr. Allison Case (Medical Investigator) at 306-653-
5222, Dr. Adrian Gamelin (Medical Investigator) at 306-653-5222, Ms. Samantha Knott 
(Administrative Assistant) at 306-653-5222 or Dr. Angela Baerwald (Scientific Investigator) at 
306-966-8073.  You may also contact the study investigators once the study is completed to enquire 
about the results of the study.  
 
If you have questions about your rights as a research subject or concerns about the study and your 
experiences while participating in this study, you can contact the Chair of the Biomedical Research 
Ethics Board at the University of Saskatchewan at 306-966-4053.  The Research Ethics Board is a 
group of individuals (scientists, physicians, ethicists, lawyers and members of the community) that 
provide an independent review of human research studies. This study has been reviewed and 
approved on ethical grounds by the University of Saskatchewan Research Ethics Board.  
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Consent to Participate (Female Partner) 
 
o I have read (or someone has read to me) the information in this consent form. 
o I understand the purpose and procedures and the possible risks and benefits of the study.  
o I was given sufficient time to think about it. 
o I had the opportunity to ask questions and have received satisfactory answers. 
o I understand that I am free to withdraw from this study at any time for any reason and the 
decision to stop taking part will not affect my future medical care. 
o I give permission for the use and disclosure of my de-identified personal health information 
collected for the research purposes described in this form. 
o I understand that by signing this document I do not waive any of my legal rights. 
o I will be given a signed and dated copy of this consent form. 
 
 
 
I agree to participate in this study: 
 
Participant Signature: ______________________________________________________________       
Participant Name (please print): ______________________________________________________ 
Date: _________________________________  Time: ___________________________ 
 
Investigator/Delegate Signature: _____________________________________________________ 
Investigator/Delegate Name (please print): _____________________________________________ 
Date: _________________________________  Time: ___________________________ 
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Consent to Participate (Male Partner) 
 
o I have read (or someone has read to me) the information in this consent form. 
o I understand the purpose and procedures and the possible risks and benefits of the study.  
o I was given sufficient time to think about it. 
o I had the opportunity to ask questions and have received satisfactory answers. 
o I understand that I am free to withdraw from this study at any time for any reason and the 
decision to stop taking part will not affect my future medical care. 
o I give permission for the use and disclosure of my de-identified personal health information 
collected for the research purposes described in this form. 
o I understand that by signing this document I do not waive any of my legal rights. 
o I will be given a signed and dated copy of this consent form. 
 
 
 
I agree to participate in this study: 
 
Participant Signature: ______________________________________________________________       
Participant Name (please print): ______________________________________________________ 
Date: _________________________________  Time: ___________________________ 
 
Investigator/Delegate Signature: _____________________________________________________ 
Investigator/Delegate Name (please print): _____________________________________________ 
Date: _________________________________  Time: ___________________________ 
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Research Participant Information Sheet 
Healthy Volunteers 
 
Endocrine Disrupting Chemicals: Potential Effects on Male and Female 
Reproductive Health in Saskatchewan 
 
Principal Investigator:  Angela Baerwald PhDa 
 
Scientific Co-Investigators: John Giesy PhDa 
    Markus Hecker PhDa 
    Paul Jones PhDa 
         
Medical Investigators: Donna Chizen MD FRCSCa  
    Allison Case MD FRCSCb 
    Adrian Gamelin MD FRCSCb 
     
Study Nurses:   Jackie McVee BScN RNb 
    April Henry RNb 
 
Research Co-ordinator Sandhya Roy MSc Candidatea 
     
Study Location:            a Department of Obstetrics, Gynecology and Reproductive Sciences 
    Royal University Hospital 
                                                103 Hospital Drive 
                                                Saskatoon, SK S7N OW8 
                                                   
                                               bAURORA Reproductive Care  
River Centre 1, 4th Floor 
    405-475  2nd Ave. S 
    Saskatoon, SK S7K 1P4 
                                              
 
Study Sponsor:  Royal University Hospital Foundation 
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Introduction: 
You are being invited to participate in a research study at the University of Saskatchewan. Please 
read the following information sheet and ask as many questions as necessary before you decide 
whether to participate. Please take time to read the following information carefully and to discuss it 
with your family, friends, and doctor before you decide. Your participation in this study is entirely 
voluntary, so it is up to you to decide whether or not to take part.  If you decide to take part in this 
study, you are free to withdraw at any time without giving any reasons for your decision. If you 
choose to withdraw from this study, you will not lose the benefit of any medical care to which you 
are entitled or are presently receiving. 
 
Who is Conducting the Study? 
This study is being conducted by scientists and physicians in the Department of Obstetrics, 
Gynecology and Reproductive Sciences at the University of Saskatchewan and the Aurora 
Reproductive Care Center. Funding to cover the administrative costs of conducting this study has 
been provided by the Royal University Hospital Foundation.  The investigators are not being paid to 
conduct this study.  The investigators have no known or potential conflicts of interest in conducting 
this study.   
 
Why is this Study being Conducted? 
Research performed primarily in animals over the past 50 years has shown that pollutants in the 
environment may be causing damage to the reproductive tissues, cells, and gametes (i.e., eggs and 
sperm). ‘Endocrine Disrupting Chemicals’ (EDCs) are of particular interest because they interfere 
with the production and/or action of hormones that control reproductive processes. Bisphenol A 
(BPA) and phthalates are EDCs to which Canadians are continuously exposed through food and 
beverage containers, air, water, soil, construction materials, and children’s toys and products. BPA 
and phthalates have been detected in human serum, semen, amniotic fluid, follicular fluid (i.e., fluid 
in the sacs in the ovaries that contain the eggs), placental tissue, and breast milk; their metabolites 
have been measured in urine. However, the potential effects of exposure on human reproductive 
health are not fully understood. Furthermore, exposure to BPA and phthalates in people living in 
Saskatchewan has not been studied in detail.  
 
The overall objective of this study is to determine whether environmental exposure to BPA and/or 
phthalates negatively affects reproductive function in women and men. We will determine whether 
concentrations of BPA and/or phthalates differ in men and women with different types of infertility 
diagnoses compared to men and women without infertility. Greater knowledge about the possible 
effects of BPA and phthalates on reproductive function may increase our understanding of the 
causes of infertility, assist in preventing reproductive disease, and improve patient care.  We believe 
that the results of our study will be of interest to the general public and government agencies 
involved in regulating the manufacturing industry. 
 
What does the Study Involve? 
Couples undergoing IVF or ICSI for assisted reproduction as well as healthy male and female 
volunteers < 40 years of age will be invited to participate. In order for infertility patients to be 
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eligible, both the male and female partners must agree to participate. Couples undergoing infertility 
treatment for the following reasons will be evaluated: 
 
1. unexplained infertility (n=30 men, n=30 women) 
2. PCOS (n=30 men, n=30 women) 
3. Male factor infertility (n=30 men, n=30 women) 
 
Couples with a combination of both male and female factor infertility will not be eligible to 
participate. 
     
 
Additional participants will be assigned to the following control groups: 
 
4. Healthy volunteers with no history or current diagnosis of reproductive dysfunction 
 (n=30 men, n=30 women) 
 
Pre-Study Visit 
If you are eligible to participate in the study, you will be asked to visit the Royal University 
Hospital for a pre-study appointment.  At this appointment, study procedures will be discussed with 
you and you may ask any questions about the study.  You will be asked to sign a consent form 
before initiating any study procedures.    
 
Study Visits 
If you agree to participate, you will will be asked to provide 1 blood sample (approximately 7 mL 
or 1 teaspoon of blood) on 3 separate days. Blood draws will be performed by physicians, nurses 
and/or researchers with training in phlebotomy (i.e., drawing blood). Appointments for blood draws 
will be made approximately 4-7 days apart. 
 
At the completion of the study all of the frozen blood samples will be transported to the Toxicology 
Center at the University of Saskatchewan. The levels of exposure to BPA and phthalates will be 
evaluated.  The samples will be destroyed upon completion of the study. 
 
You will have completed all study-related procedures once you undergo the 3 blood draws. 
 
What are the Possible Risks and Discomforts? 
Potential risks during study participation include: 
   -discomfort and bruising at the site of the blood draw 
 
What are the Benefits of Participating in this Study? 
There are no direct benefits for you or your partner to participate in this study. We believe that the 
results of this study may increase our understanding of the causes of male and female infertility and 
assist in the development of better treatment options for women with reproductive dysfunction.   
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What Will the Study Cost Me? 
You will not be charged for participating in this study.  You will not be paid for participating in this 
study.   
 
Will My Participation be Kept Confidential? 
In Saskatchewan, the Health Information Protection Act (HIPA) protects the privacy of your 
personal health information. Your privacy will be respected. Your name will not be attached to any 
information, nor mentioned in any study report, nor be made available to anyone except the 
research team.  It is the intention of the research team to publish results of this research in scientific 
journals and to present the findings at related conferences and workshops, but your identity will not 
be revealed. 
 
What Happens if I Decide to Withdraw from the Study? 
Your participation in this study is voluntary. You may decide not to participate or withdraw at any 
time. You do not have to provide a reason to withdraw from the study.  If you choose not to 
participate in or withdraw from the study, it will not affect your future medical care. 
 
Please notify the study personnel as soon as possible if you wish to withdraw from the study.  If you 
voluntarily withdraw from the study and you do not want your data to be used in the study, your 
samples will be destroyed. 
 
Who Do I Contact if We Have Questions About the Study? 
If you have any questions regarding your participation in this study, please feel free to contact 
Sandhya Roy (Research Co-ordinator) at 306-966-7851. Dr. Donna Chizen (Medical Investigator) 
at 306-966-8623, or Dr. Angela Baerwald (Scientific Investigator) at 306-966-8073. You may also 
contact the study investigators once the study is completed to enquire about the results of the study.  
 
If you have questions about your rights as a research subject or concerns about the study and your 
experiences while participating in this study, you can contact the Chair of the Biomedical Research 
Ethics Board at the University of Saskatchewan at 306-966-4053.  The Research Ethics Board is a 
group of individuals (scientists, physicians, ethicists, lawyers and members of the community) that 
provide an independent review of human research studies. This study has been reviewed and 
approved on ethical grounds by the University of Saskatchewan Research Ethics Board.  
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Consent to Participate 
 
o I have read (or someone has read to me) the information in this consent form. 
o I understand the purpose and procedures and the possible risks and benefits of the study.  
o I was given sufficient time to think about it. 
o I had the opportunity to ask questions and have received satisfactory answers. 
o I understand that I am free to withdraw from this study at any time for any reason and the 
decision to stop taking part will not affect my future medical care. 
o I give permission for the use and disclosure of my de-identified personal health information 
collected for the research purposes described in this form. 
o I understand that by signing this document I do not waive any of my legal rights. 
o I will be given a signed and dated copy of this consent form. 
 
 
 
I agree to participate in this study: 
 
Participant Signature: ______________________________________________________________       
Participant Name (please print): ______________________________________________________ 
Date: _________________________________  Time: ___________________________ 
 
Investigator/Delegate Signature: _____________________________________________________ 
Investigator/Delegate Name (please print): _____________________________________________ 
Date: _________________________________  Time: ___________________________ 
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Figure 6.3.1:  An example of a standard chromatogram.  These graphs illustrate the data [ run time 
in x axis (in min) and analyte peak area (an arbitrary unit) in y axis] which were used 
to identify one and/ or two products/daughter ions (i.e., DEHP, DBP, DIDP and 
internal standard in a standard) based on their retention time (RT).  Arrows indicate 
the similar RT for two products ions of a precursor ion, and different RTs for each 
precursor ion.   
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Figure 6.3.2:  An example of a sample chromatogram.  Graphs illustrate run time on the x axis (in 
min) and analyte peak area (an arbitrary unit) on the y axis. These data were used to 
identify one and/ or two products/daughter ions (i.e., DEHP, DBP, DIDP and 
internal standard in a standard) based on their retention time (RT).  Arrows indicate 
the similar RT for two products ions of a precursor ion, and different RTs for each 
precursor ion.   
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